The updated landscape of tumor microenvironment and drug repurposing
Accumulating evidence shows that cellular and acellular components in tumor microenvironment (TME) can reprogram tumor initiation, growth, invasion, metastasis, and response to therapies. Cancer research and treatment have switched from a cancer-centric model to a TME-centric one, considering the in...
Saved in:
| Published in | Signal transduction and targeted therapy Vol. 5; no. 1; p. 166 |
|---|---|
| Main Authors | , |
| Format | Journal Article |
| Language | English |
| Published |
London
Nature Publishing Group UK
25.08.2020
Nature Publishing Group |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Accumulating evidence shows that cellular and acellular components in tumor microenvironment (TME) can reprogram tumor initiation, growth, invasion, metastasis, and response to therapies. Cancer research and treatment have switched from a cancer-centric model to a TME-centric one, considering the increasing significance of TME in cancer biology. Nonetheless, the clinical efficacy of therapeutic strategies targeting TME, especially the specific cells or pathways of TME, remains unsatisfactory. Classifying the chemopathological characteristics of TME and crosstalk among one another can greatly benefit further studies exploring effective treating methods. Herein, we present an updated image of TME with emphasis on hypoxic niche, immune microenvironment, metabolism microenvironment, acidic niche, innervated niche, and mechanical microenvironment. We then summarize conventional drugs including aspirin, celecoxib, β-adrenergic antagonist, metformin, and statin in new antitumor application. These drugs are considered as viable candidates for combination therapy due to their antitumor activity and extensive use in clinical practice. We also provide our outlook on directions and potential applications of TME theory. This review depicts a comprehensive and vivid landscape of TME from biology to treatment. |
|---|---|
| AbstractList | Accumulating evidence shows that cellular and acellular components in tumor microenvironment (TME) can reprogram tumor initiation, growth, invasion, metastasis, and response to therapies. Cancer research and treatment have switched from a cancer-centric model to a TME-centric one, considering the increasing significance of TME in cancer biology. Nonetheless, the clinical efficacy of therapeutic strategies targeting TME, especially the specific cells or pathways of TME, remains unsatisfactory. Classifying the chemopathological characteristics of TME and crosstalk among one another can greatly benefit further studies exploring effective treating methods. Herein, we present an updated image of TME with emphasis on hypoxic niche, immune microenvironment, metabolism microenvironment, acidic niche, innervated niche, and mechanical microenvironment. We then summarize conventional drugs including aspirin, celecoxib, β-adrenergic antagonist, metformin, and statin in new antitumor application. These drugs are considered as viable candidates for combination therapy due to their antitumor activity and extensive use in clinical practice. We also provide our outlook on directions and potential applications of TME theory. This review depicts a comprehensive and vivid landscape of TME from biology to treatment. Accumulating evidence shows that cellular and acellular components in tumor microenvironment (TME) can reprogram tumor initiation, growth, invasion, metastasis, and response to therapies. Cancer research and treatment have switched from a cancer-centric model to a TME-centric one, considering the increasing significance of TME in cancer biology. Nonetheless, the clinical efficacy of therapeutic strategies targeting TME, especially the specific cells or pathways of TME, remains unsatisfactory. Classifying the chemopathological characteristics of TME and crosstalk among one another can greatly benefit further studies exploring effective treating methods. Herein, we present an updated image of TME with emphasis on hypoxic niche, immune microenvironment, metabolism microenvironment, acidic niche, innervated niche, and mechanical microenvironment. We then summarize conventional drugs including aspirin, celecoxib, β-adrenergic antagonist, metformin, and statin in new antitumor application. These drugs are considered as viable candidates for combination therapy due to their antitumor activity and extensive use in clinical practice. We also provide our outlook on directions and potential applications of TME theory. This review depicts a comprehensive and vivid landscape of TME from biology to treatment.Accumulating evidence shows that cellular and acellular components in tumor microenvironment (TME) can reprogram tumor initiation, growth, invasion, metastasis, and response to therapies. Cancer research and treatment have switched from a cancer-centric model to a TME-centric one, considering the increasing significance of TME in cancer biology. Nonetheless, the clinical efficacy of therapeutic strategies targeting TME, especially the specific cells or pathways of TME, remains unsatisfactory. Classifying the chemopathological characteristics of TME and crosstalk among one another can greatly benefit further studies exploring effective treating methods. Herein, we present an updated image of TME with emphasis on hypoxic niche, immune microenvironment, metabolism microenvironment, acidic niche, innervated niche, and mechanical microenvironment. We then summarize conventional drugs including aspirin, celecoxib, β-adrenergic antagonist, metformin, and statin in new antitumor application. These drugs are considered as viable candidates for combination therapy due to their antitumor activity and extensive use in clinical practice. We also provide our outlook on directions and potential applications of TME theory. This review depicts a comprehensive and vivid landscape of TME from biology to treatment. |
| ArticleNumber | 166 |
| Author | Jin, Ming-Zhu Jin, Wei-Lin |
| Author_xml | – sequence: 1 givenname: Ming-Zhu surname: Jin fullname: Jin, Ming-Zhu organization: Institute of Nano Biomedicine and Engineering, Shanghai Engineering Center for Intelligent Diagnosis and Treatment Instrument, Department of Instrument Science and Engineering, Key Laboratory for Thin Film and Microfabrication Technology of Ministry of Education, School of Electronic Information and Electronic Engineering, Shanghai Jiao Tong University, Shanghai Jiao Tong University School of Medicine – sequence: 2 givenname: Wei-Lin orcidid: 0000-0001-8011-2405 surname: Jin fullname: Jin, Wei-Lin email: weilinjin@sjtu.edu.cn organization: Institute of Nano Biomedicine and Engineering, Shanghai Engineering Center for Intelligent Diagnosis and Treatment Instrument, Department of Instrument Science and Engineering, Key Laboratory for Thin Film and Microfabrication Technology of Ministry of Education, School of Electronic Information and Electronic Engineering, Shanghai Jiao Tong University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32843638$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kUtv1TAQhS1URJ9_gAWKxIZNYPyKfTeVUKGAVIlNWVuOM7l1ldipnVy1_76-3NKWLrrySPOd8Zk5h2QvxICEvKfwmQLXX7KgfMVqYFADMA317RtywECuat5wufes3icnOV8DAG24UlK8I_ucaVFa-oB8u7zCapk6O2NXDTZ02dkJq9hX8zLGVI3epYhh41MMI4a5KkjVpWVdJZyWNMXsw_qYvO3tkPHk4T0if86_X579rC9-__h19vWidlLAXLeylT1njeUoOpCCSqdZq_tVR7FYs1rJtgeOnCnKnXC60wp1Aw1ap6Ww_Iic7uZOSzti54qfZAczJT_adGei9eb_TvBXZh03RgmhGsHKgE8PA1K8WTDPZvTZ4VAWx7hkwwRXAqjUqqAfX6DXcUmhrLelmpUqpCzUh-eOHq38O3AB2A4oZ8w5Yf-IUDDbIM0uSFOCNH-DNLdFpF-InJ_t7ON2Kz-8LuU7aS7_hDWmJ9uvqO4BVZiy0A |
| CitedBy_id | crossref_primary_10_1038_s41525_021_00215_7 crossref_primary_10_1016_j_jid_2023_05_030 crossref_primary_10_1016_j_canlet_2025_217618 crossref_primary_10_3390_biom12101412 crossref_primary_10_3390_biomedicines9091159 crossref_primary_10_3390_metabo13050618 crossref_primary_10_3390_ijms23042261 crossref_primary_10_1007_s12672_024_01186_8 crossref_primary_10_1016_j_ejphar_2023_176013 crossref_primary_10_1016_j_intimp_2024_113850 crossref_primary_10_31083_j_fbl2903098 crossref_primary_10_3389_fimmu_2023_1230534 crossref_primary_10_1089_ten_teb_2024_0088 crossref_primary_10_24931_2413_9432_2024_13_2_9_18 crossref_primary_10_1038_s41421_023_00559_7 crossref_primary_10_3389_fimmu_2022_897754 crossref_primary_10_3390_ijms25147737 crossref_primary_10_1038_s41388_023_02909_x crossref_primary_10_1038_s41419_024_06503_1 crossref_primary_10_1088_1758_5090_ad6d8c crossref_primary_10_3389_fimmu_2025_1537947 crossref_primary_10_1016_j_bbcan_2025_189264 crossref_primary_10_1038_s41598_023_37311_w crossref_primary_10_1007_s00262_024_03685_7 crossref_primary_10_1142_S1793545823300070 crossref_primary_10_1186_s13046_022_02592_y crossref_primary_10_3389_fimmu_2022_861328 crossref_primary_10_1186_s13578_024_01199_4 crossref_primary_10_1016_j_addr_2021_113907 crossref_primary_10_1016_j_intimp_2024_111548 crossref_primary_10_1021_acsbiomaterials_4c00445 crossref_primary_10_3390_biom14121579 crossref_primary_10_2147_IJN_S440387 crossref_primary_10_1038_s41598_023_36872_0 crossref_primary_10_3389_fimmu_2021_802080 crossref_primary_10_1515_mr_2021_0032 crossref_primary_10_1186_s12951_022_01309_9 crossref_primary_10_3389_fimmu_2021_701006 crossref_primary_10_1002_cam4_5383 crossref_primary_10_1038_s41420_022_01163_6 crossref_primary_10_1038_s41467_025_55905_y crossref_primary_10_1038_s41419_023_06389_5 crossref_primary_10_3389_fchem_2021_686303 crossref_primary_10_1016_j_nantod_2022_101376 crossref_primary_10_3389_fphar_2022_909526 crossref_primary_10_12677_ACM_2024_141137 crossref_primary_10_1002_chem_202404006 crossref_primary_10_1016_j_onano_2022_100097 crossref_primary_10_1080_13543784_2021_1865308 crossref_primary_10_4103_aja202186 crossref_primary_10_1007_s12672_024_01513_z crossref_primary_10_3389_fbiom_2024_1347324 crossref_primary_10_1016_j_phymed_2023_154900 crossref_primary_10_1093_stmcls_sxac036 crossref_primary_10_1007_s12609_022_00451_5 crossref_primary_10_3390_biomedicines10051103 crossref_primary_10_3390_pharmaceutics14102195 crossref_primary_10_1016_j_actbio_2023_03_014 crossref_primary_10_3389_fphy_2022_915644 crossref_primary_10_3892_or_2024_8814 crossref_primary_10_1016_j_cej_2024_159137 crossref_primary_10_1038_s41598_024_72679_3 crossref_primary_10_1038_s41388_023_02778_4 crossref_primary_10_1016_j_heliyon_2024_e33219 crossref_primary_10_3390_ijms25168899 crossref_primary_10_4110_in_2022_22_e6 crossref_primary_10_3389_fimmu_2021_803014 crossref_primary_10_1016_j_ejphar_2024_176639 crossref_primary_10_1007_s00383_024_05647_7 crossref_primary_10_1038_s41392_024_01808_1 crossref_primary_10_3390_cancers13030499 crossref_primary_10_3390_cancers13112759 crossref_primary_10_18632_aging_205921 crossref_primary_10_1016_j_nantod_2023_101882 crossref_primary_10_1016_j_addr_2022_114360 crossref_primary_10_3390_cimb46060346 crossref_primary_10_3390_biology10020129 crossref_primary_10_1016_j_bulcan_2021_02_005 crossref_primary_10_1038_s41401_025_01517_7 crossref_primary_10_1016_j_jare_2024_11_010 crossref_primary_10_1016_j_ymthe_2023_02_010 crossref_primary_10_3389_fonc_2021_746058 crossref_primary_10_1186_s12885_025_13731_x crossref_primary_10_1002_smll_202402311 crossref_primary_10_2174_1568026623666221014152759 crossref_primary_10_1093_stcltm_szac002 crossref_primary_10_1038_s41597_024_03018_4 crossref_primary_10_1186_s12876_023_03045_2 crossref_primary_10_2147_CMAR_S474348 crossref_primary_10_1016_j_gene_2022_147052 crossref_primary_10_3390_cancers13194746 crossref_primary_10_1007_s00438_024_02156_z crossref_primary_10_1038_s41419_024_06536_6 crossref_primary_10_3389_fphar_2023_1103547 crossref_primary_10_1038_s41565_022_01261_7 crossref_primary_10_3389_fimmu_2022_966661 crossref_primary_10_1186_s12935_022_02580_4 crossref_primary_10_3390_cancers16193339 crossref_primary_10_1007_s12672_025_02081_6 crossref_primary_10_1016_j_canlet_2025_217539 crossref_primary_10_1186_s13046_024_02949_5 crossref_primary_10_31083_j_fbl2902087 crossref_primary_10_3390_biomedicines12030529 crossref_primary_10_1038_s41401_024_01355_z crossref_primary_10_1039_D3BM00254C crossref_primary_10_1177_15347354231178903 crossref_primary_10_1016_j_nano_2024_102743 crossref_primary_10_1134_S0006297924140086 crossref_primary_10_1016_j_heliyon_2024_e33277 crossref_primary_10_1186_s13045_024_01578_x crossref_primary_10_1016_j_drup_2021_100796 crossref_primary_10_1016_j_drup_2024_101125 crossref_primary_10_3390_cancers14092291 crossref_primary_10_3389_fonc_2024_1363695 crossref_primary_10_3390_cancers16112104 crossref_primary_10_1016_j_rechem_2024_101372 crossref_primary_10_1039_D4TB00680A crossref_primary_10_3390_biomedicines9121921 crossref_primary_10_3389_fmolb_2023_1284623 crossref_primary_10_1016_j_gendis_2025_101569 crossref_primary_10_1016_j_ccell_2023_01_010 crossref_primary_10_3390_nano12183145 crossref_primary_10_1002_adfm_202311914 crossref_primary_10_1177_10104283241313441 crossref_primary_10_1016_j_biopha_2023_114609 crossref_primary_10_1136_jitc_2022_005282 crossref_primary_10_1016_j_lrr_2021_100268 crossref_primary_10_3389_fmmed_2022_1055028 crossref_primary_10_3390_biomedicines11123111 crossref_primary_10_3389_fimmu_2022_921894 crossref_primary_10_1007_s11538_024_01391_0 crossref_primary_10_1093_pcmedi_pbac005 crossref_primary_10_3389_fphar_2023_1175702 crossref_primary_10_3389_fmed_2022_950309 crossref_primary_10_1039_D1NR01506K crossref_primary_10_1136_jitc_2021_002841 crossref_primary_10_3389_fimmu_2024_1366096 crossref_primary_10_1007_s00432_023_04626_0 crossref_primary_10_3390_cancers12113162 crossref_primary_10_1007_s00018_023_04902_9 crossref_primary_10_1016_S1875_5364_24_60685_0 crossref_primary_10_3892_or_2024_8736 crossref_primary_10_1007_s11051_024_06198_7 crossref_primary_10_1038_s41598_023_49750_6 crossref_primary_10_1038_s41392_022_01102_y crossref_primary_10_1186_s12943_023_01860_5 crossref_primary_10_3389_fphar_2024_1324140 crossref_primary_10_3390_pharmaceutics14040821 crossref_primary_10_2967_jnumed_122_265248 crossref_primary_10_3389_fcimb_2023_1273254 crossref_primary_10_1186_s40164_023_00394_2 crossref_primary_10_1016_j_fmre_2024_03_014 crossref_primary_10_1016_j_ejphar_2023_176124 crossref_primary_10_62347_SMSG9047 crossref_primary_10_1007_s10528_023_10616_1 crossref_primary_10_1038_s41588_024_01874_9 crossref_primary_10_1002_mog2_68 crossref_primary_10_1080_13543784_2024_2348068 crossref_primary_10_1007_s00253_024_13378_x crossref_primary_10_1016_j_cyto_2022_155909 crossref_primary_10_1038_s41419_022_04976_6 crossref_primary_10_1038_s41598_025_88376_8 crossref_primary_10_1002_adma_202206915 crossref_primary_10_1007_s10565_023_09808_7 crossref_primary_10_1186_s40164_025_00627_6 crossref_primary_10_1016_j_carbon_2023_118095 crossref_primary_10_1038_s41417_024_00765_9 crossref_primary_10_1002_advs_202402345 crossref_primary_10_3390_polym15112482 crossref_primary_10_1126_scisignal_abj3490 crossref_primary_10_1136_jitc_2021_003472 crossref_primary_10_1002_advs_202400049 crossref_primary_10_3389_fimmu_2020_620166 crossref_primary_10_1016_j_omtn_2022_08_028 crossref_primary_10_3389_fimmu_2021_767939 crossref_primary_10_1002_cti2_1400 crossref_primary_10_1016_j_bbcan_2024_189142 crossref_primary_10_1016_j_heliyon_2023_e13989 crossref_primary_10_1080_13543776_2024_2391288 crossref_primary_10_1002_adhm_202303631 crossref_primary_10_3389_fimmu_2023_1148061 crossref_primary_10_1007_s00210_025_03961_y crossref_primary_10_3390_ijms241512222 crossref_primary_10_18632_aging_205663 crossref_primary_10_1038_s41416_022_01703_y crossref_primary_10_1002_smll_202311101 crossref_primary_10_1016_j_heliyon_2025_e42977 crossref_primary_10_3390_ph15121523 crossref_primary_10_3389_fonc_2024_1428018 crossref_primary_10_1007_s11596_023_2763_0 crossref_primary_10_3389_fimmu_2023_1219209 crossref_primary_10_1016_j_bcp_2024_116492 crossref_primary_10_1002_ijc_34702 crossref_primary_10_3389_fcell_2024_1401945 crossref_primary_10_1007_s12672_025_01863_2 crossref_primary_10_1016_j_biopha_2022_113863 crossref_primary_10_31083_j_fbl2804077 crossref_primary_10_1016_j_immuni_2023_01_014 crossref_primary_10_1152_physiol_00010_2023 crossref_primary_10_3390_ijms222212389 crossref_primary_10_1007_s11010_023_04715_1 crossref_primary_10_1186_s40478_025_01939_8 crossref_primary_10_1186_s12967_022_03510_8 crossref_primary_10_1002_adma_202304172 crossref_primary_10_1002_iub_2461 crossref_primary_10_3389_fonc_2021_718636 crossref_primary_10_3389_fimmu_2022_844931 crossref_primary_10_1166_jbn_2021_3030 crossref_primary_10_1186_s12864_024_10055_1 crossref_primary_10_1038_s41598_024_72538_1 crossref_primary_10_3390_cancers15041282 crossref_primary_10_1039_D0TB02190C crossref_primary_10_3389_fimmu_2023_1153423 crossref_primary_10_3390_molecules27010137 crossref_primary_10_1016_j_biopha_2024_116783 crossref_primary_10_1080_14796694_2024_2355081 crossref_primary_10_1186_s12943_024_02165_x crossref_primary_10_3389_fimmu_2023_1277243 crossref_primary_10_1007_s12262_023_03828_7 crossref_primary_10_1016_j_bbrc_2024_150172 crossref_primary_10_3390_biomedicines10051065 crossref_primary_10_1038_s41419_024_06424_z crossref_primary_10_3389_fimmu_2024_1499301 crossref_primary_10_1016_j_jare_2022_04_006 crossref_primary_10_3389_fimmu_2022_900273 crossref_primary_10_1021_acsmaterialslett_4c01267 crossref_primary_10_3389_fonc_2023_1116016 crossref_primary_10_3390_cancers16233976 crossref_primary_10_1016_j_bbcan_2024_189244 crossref_primary_10_1002_adfm_202419912 crossref_primary_10_1016_j_jconrel_2023_01_043 crossref_primary_10_1186_s12967_025_06306_8 crossref_primary_10_2147_IJN_S459710 crossref_primary_10_3390_cancers15010196 crossref_primary_10_1016_j_critrevonc_2025_104705 crossref_primary_10_3390_cancers14081983 crossref_primary_10_1002_mco2_164 crossref_primary_10_2174_0118744710283369240328082442 crossref_primary_10_1111_jcmm_17927 crossref_primary_10_3390_ijms23136931 crossref_primary_10_1089_genbio_2023_0032 crossref_primary_10_1186_s12935_023_03106_2 crossref_primary_10_1039_D4NR00537F crossref_primary_10_1016_j_ijpharm_2025_125479 crossref_primary_10_1016_j_bbrc_2024_150066 crossref_primary_10_1016_j_actbio_2023_01_039 crossref_primary_10_3389_fimmu_2022_968755 crossref_primary_10_1002_cam4_4114 crossref_primary_10_1097_JS9_0000000000000483 crossref_primary_10_1002_adhm_202202609 crossref_primary_10_1186_s12951_022_01692_3 crossref_primary_10_1016_j_heliyon_2022_e10164 crossref_primary_10_1002_adma_202100241 crossref_primary_10_1016_j_cej_2022_135813 crossref_primary_10_1016_j_bbcan_2024_189137 crossref_primary_10_3389_fmolb_2021_796385 crossref_primary_10_62347_PALH4103 crossref_primary_10_1111_febs_17278 crossref_primary_10_1186_s12864_024_10283_5 crossref_primary_10_3390_cancers15071927 crossref_primary_10_3389_fphar_2024_1442888 crossref_primary_10_1016_j_jep_2025_119636 crossref_primary_10_1016_j_ccell_2023_03_008 crossref_primary_10_1016_j_ijbiomac_2023_125878 crossref_primary_10_1021_acsnano_3c01645 crossref_primary_10_1186_s12967_024_05940_y crossref_primary_10_1016_j_trsl_2022_08_003 crossref_primary_10_1002_adhm_202404265 crossref_primary_10_1038_s41598_023_40592_w crossref_primary_10_20517_2394_5079_2023_53 crossref_primary_10_1021_acsabm_1c00591 crossref_primary_10_3724_abbs_2023092 crossref_primary_10_3389_fphar_2023_1148706 crossref_primary_10_1038_s41392_024_01961_7 crossref_primary_10_1158_0008_5472_CAN_23_0258 crossref_primary_10_3390_pathogens10080969 crossref_primary_10_1073_pnas_2200230119 crossref_primary_10_1186_s12943_023_01877_w crossref_primary_10_1186_s12964_023_01062_y crossref_primary_10_1007_s10555_023_10095_1 crossref_primary_10_1007_s00259_021_05475_0 crossref_primary_10_1186_s12935_024_03586_w crossref_primary_10_3389_fonc_2021_618187 crossref_primary_10_1007_s12195_024_00798_y crossref_primary_10_1177_1721727X221133708 crossref_primary_10_3390_biology13100846 crossref_primary_10_3389_fimmu_2023_1264179 crossref_primary_10_1021_acs_chemrev_1c00666 crossref_primary_10_1089_genbio_2023_29115_sro crossref_primary_10_1166_mex_2024_2644 crossref_primary_10_1021_acsami_1c04310 crossref_primary_10_3390_genes13050787 crossref_primary_10_1097_CCO_0000000000000908 crossref_primary_10_1016_j_jddst_2024_106594 crossref_primary_10_1177_10668969241291882 crossref_primary_10_14348_molcells_2023_2178 crossref_primary_10_3390_cancers14184465 crossref_primary_10_3389_fimmu_2021_697083 crossref_primary_10_1002_INMD_20230062 crossref_primary_10_1039_D2NA00823H crossref_primary_10_1021_acs_chemmater_3c02472 crossref_primary_10_1080_19490976_2024_2310215 crossref_primary_10_1016_j_addr_2022_114321 crossref_primary_10_1016_j_matdes_2024_113097 crossref_primary_10_1021_acsami_4c13358 crossref_primary_10_1186_s12951_024_02992_6 crossref_primary_10_1186_s12865_023_00552_5 crossref_primary_10_3390_cancers15010153 crossref_primary_10_1038_s41598_024_57296_4 crossref_primary_10_3390_cancers15010276 crossref_primary_10_1002_cac2_12291 crossref_primary_10_1016_j_bbcan_2024_189205 crossref_primary_10_3390_nano13162380 crossref_primary_10_3389_fimmu_2023_1171141 crossref_primary_10_3389_fimmu_2023_1175503 crossref_primary_10_3390_cancers16183222 crossref_primary_10_1016_j_intimp_2024_113347 crossref_primary_10_1016_j_xcrm_2023_101294 crossref_primary_10_1038_s41598_023_44598_2 crossref_primary_10_1158_0008_5472_CAN_23_2650 crossref_primary_10_3390_genes14081599 crossref_primary_10_1016_j_canlet_2024_216894 crossref_primary_10_2478_acb_2024_0024 crossref_primary_10_1186_s12943_024_02069_w crossref_primary_10_1002_adhm_202303543 crossref_primary_10_1007_s11684_023_1048_0 crossref_primary_10_15252_embj_2021108647 crossref_primary_10_1002_advs_202301661 crossref_primary_10_3389_fphar_2024_1466017 crossref_primary_10_3390_biom14020190 crossref_primary_10_1186_s12929_022_00866_3 crossref_primary_10_1016_j_diii_2022_10_011 crossref_primary_10_1155_2022_6022869 crossref_primary_10_1155_2023_5512781 crossref_primary_10_1186_s13045_022_01305_4 crossref_primary_10_1002_adhm_202303481 crossref_primary_10_1126_sciadv_adi8986 crossref_primary_10_3390_ijms22094720 crossref_primary_10_1016_j_colsurfa_2024_134346 crossref_primary_10_3748_wjg_v29_i42_5699 crossref_primary_10_1038_s41401_023_01169_5 crossref_primary_10_1002_adhm_202201442 crossref_primary_10_1002_biot_202300162 crossref_primary_10_3390_ijms23168940 crossref_primary_10_3389_fonc_2023_1091488 crossref_primary_10_1016_j_carbpol_2022_120493 crossref_primary_10_3390_biomedicines9040374 crossref_primary_10_1097_PPO_0000000000000615 crossref_primary_10_2147_NSA_S437812 crossref_primary_10_1016_j_biosystems_2021_104385 crossref_primary_10_3390_cancers15113009 crossref_primary_10_1002_adtp_202300442 crossref_primary_10_1007_s10571_024_01484_3 crossref_primary_10_3389_fcell_2021_641469 crossref_primary_10_3390_molecules28186438 crossref_primary_10_3389_fimmu_2024_1408377 crossref_primary_10_1002_ctm2_696 crossref_primary_10_1097_PPO_0000000000000740 crossref_primary_10_3389_fonc_2022_1034842 crossref_primary_10_1186_s13048_023_01312_0 crossref_primary_10_3390_cancers17060958 crossref_primary_10_1039_D3NR01735D crossref_primary_10_3389_fimmu_2022_971428 crossref_primary_10_1186_s12943_024_02218_1 crossref_primary_10_1158_1078_0432_CCR_23_1111 crossref_primary_10_2174_0113892029300608240531111743 crossref_primary_10_1007_s13770_021_00403_7 crossref_primary_10_1016_j_jsbmb_2025_106729 crossref_primary_10_1186_s13046_021_02041_2 crossref_primary_10_3389_fonc_2021_800235 crossref_primary_10_1002_cam4_6804 crossref_primary_10_1007_s11912_022_01335_8 crossref_primary_10_1016_j_heliyon_2024_e36164 crossref_primary_10_1007_s11517_024_03199_5 crossref_primary_10_3390_biology10050425 crossref_primary_10_1016_j_cej_2022_137383 crossref_primary_10_3389_fimmu_2020_577869 crossref_primary_10_1186_s12943_024_02183_9 crossref_primary_10_1158_1078_0432_CCR_22_0980 crossref_primary_10_3390_biomedicines12010109 crossref_primary_10_1016_j_tcb_2023_03_011 crossref_primary_10_1016_j_heliyon_2024_e30505 crossref_primary_10_1016_j_actbio_2021_03_002 crossref_primary_10_1186_s13048_022_01065_2 crossref_primary_10_1038_s41598_024_74206_w crossref_primary_10_1038_s41598_023_47781_7 crossref_primary_10_3390_ijms22083863 crossref_primary_10_1038_s41420_024_02106_z crossref_primary_10_3389_fcell_2025_1485422 crossref_primary_10_3390_cancers14246267 crossref_primary_10_1515_ntrev_2024_0134 crossref_primary_10_3390_cells12030389 crossref_primary_10_1002_cnr2_2050 crossref_primary_10_3390_cancers15010100 crossref_primary_10_1002_cac2_12416 crossref_primary_10_3390_cancers13174471 crossref_primary_10_3389_fimmu_2022_882718 crossref_primary_10_1002_iid3_70098 crossref_primary_10_1002_ijc_33594 crossref_primary_10_1186_s12943_023_01737_7 crossref_primary_10_3389_fimmu_2024_1352454 crossref_primary_10_1002_adfm_202101826 crossref_primary_10_1016_j_cej_2024_157746 crossref_primary_10_1063_5_0199161 crossref_primary_10_1177_03009858231207025 crossref_primary_10_1007_s40618_021_01729_8 crossref_primary_10_3390_biomedicines11082160 crossref_primary_10_1158_1541_7786_MCR_21_0781 crossref_primary_10_3390_pharmaceutics15071872 crossref_primary_10_1016_j_biopha_2023_115390 crossref_primary_10_1007_s12291_023_01166_9 crossref_primary_10_3390_biom15030323 crossref_primary_10_1016_j_biopha_2022_113096 crossref_primary_10_1007_s00262_021_03076_2 crossref_primary_10_3390_molecules27031017 crossref_primary_10_3390_pharmaceutics15010083 crossref_primary_10_1158_1541_7786_MCR_21_0786 crossref_primary_10_54457_DR_202302001 crossref_primary_10_18632_aging_205104 crossref_primary_10_1016_j_trecan_2022_12_008 crossref_primary_10_3389_fimmu_2023_1250624 crossref_primary_10_3390_pharmaceutics15061711 crossref_primary_10_1016_j_ejphar_2023_175991 crossref_primary_10_2147_IJN_S460874 crossref_primary_10_3390_cells12121560 crossref_primary_10_3390_pharmaceutics16030345 crossref_primary_10_1007_s00432_023_05486_4 crossref_primary_10_1007_s10495_023_01879_5 crossref_primary_10_1080_17460441_2021_1916464 crossref_primary_10_1155_2024_1608582 crossref_primary_10_3390_pharmaceutics14112451 crossref_primary_10_51847_PJ1xCWaW3U crossref_primary_10_1016_j_bbcan_2020_188497 crossref_primary_10_1128_jvi_01024_24 crossref_primary_10_3390_cancers14041023 crossref_primary_10_3390_cancers14163908 crossref_primary_10_3390_cancers14194886 crossref_primary_10_1002_adhm_202200690 crossref_primary_10_1038_s41597_025_04489_9 crossref_primary_10_3389_fphar_2023_1336685 crossref_primary_10_1002_smtd_202100276 crossref_primary_10_1002_adma_202300216 crossref_primary_10_1155_2021_5512156 crossref_primary_10_3390_pathogens10111446 crossref_primary_10_1016_j_ijbiomac_2024_133404 crossref_primary_10_3389_fphar_2022_1035217 crossref_primary_10_3389_fgene_2021_625236 crossref_primary_10_1021_acs_bioconjchem_1c00437 crossref_primary_10_1002_cnr2_2078 crossref_primary_10_3390_ijms25073779 crossref_primary_10_3389_fgene_2022_1001374 crossref_primary_10_3389_fimmu_2024_1483721 crossref_primary_10_1016_j_biopha_2024_116409 crossref_primary_10_1016_j_ygeno_2022_110520 crossref_primary_10_1016_j_snb_2020_129121 crossref_primary_10_1021_acsnano_3c06019 crossref_primary_10_3390_ijms24043129 crossref_primary_10_1073_pnas_2219298120 crossref_primary_10_1080_17460441_2022_1991306 crossref_primary_10_3390_cancers16091727 crossref_primary_10_3390_cancers14215416 crossref_primary_10_1016_j_pharmthera_2024_108750 crossref_primary_10_1186_s12967_022_03736_6 crossref_primary_10_3389_fimmu_2022_950536 crossref_primary_10_3390_ijms23095253 crossref_primary_10_1016_j_bbcan_2022_188703 crossref_primary_10_1038_s41420_022_01255_3 crossref_primary_10_1016_j_isci_2021_103617 crossref_primary_10_1016_j_bioactmat_2022_04_011 crossref_primary_10_1038_s41598_023_40662_z crossref_primary_10_3389_fonc_2022_877657 crossref_primary_10_3390_cancers14112608 crossref_primary_10_1111_cpr_13806 crossref_primary_10_1016_j_jconrel_2022_10_004 crossref_primary_10_3389_fbioe_2022_888431 crossref_primary_10_54457_DR_202301006 crossref_primary_10_1016_j_biomaterials_2022_121576 crossref_primary_10_1063_5_0206058 crossref_primary_10_1097_CAD_0000000000001098 crossref_primary_10_1002_adma_202312219 crossref_primary_10_1002_ptr_7755 crossref_primary_10_3390_cancers13123060 crossref_primary_10_3389_fcell_2022_803947 crossref_primary_10_1088_1758_5090_ad9b50 crossref_primary_10_1039_D4QI00523F crossref_primary_10_3390_cells11192967 crossref_primary_10_1002_btm2_10702 crossref_primary_10_1016_j_xjidi_2023_100197 crossref_primary_10_1021_acs_nanolett_4c02342 crossref_primary_10_1097_JCMA_0000000000000535 crossref_primary_10_1142_S1793545822500353 crossref_primary_10_1038_s41598_023_32321_0 crossref_primary_10_1158_1541_7786_MCR_21_0317 crossref_primary_10_3390_cancers16244145 crossref_primary_10_1016_j_jbo_2023_100487 crossref_primary_10_1021_acsnano_2c12123 crossref_primary_10_1093_bioinformatics_btae028 crossref_primary_10_3389_fonc_2022_833741 crossref_primary_10_1016_j_cej_2021_131120 crossref_primary_10_1186_s12974_024_03222_4 crossref_primary_10_3389_fimmu_2025_1505509 crossref_primary_10_3389_fonc_2025_1503300 crossref_primary_10_3390_genes13081405 crossref_primary_10_3390_ijms25063406 crossref_primary_10_1007_s00381_024_06461_1 crossref_primary_10_1007_s00262_024_03820_4 crossref_primary_10_1111_imm_13667 crossref_primary_10_3390_cancers13061316 crossref_primary_10_1016_j_pharmthera_2024_108765 crossref_primary_10_3390_ph16060808 crossref_primary_10_1186_s13046_023_02942_4 crossref_primary_10_1016_j_ccr_2023_215027 crossref_primary_10_3389_fimmu_2021_671595 crossref_primary_10_1038_s41408_024_01050_6 crossref_primary_10_1186_s12885_023_10904_4 crossref_primary_10_3389_fonc_2022_1031728 crossref_primary_10_37349_ei_2023_00108 crossref_primary_10_1021_acsnano_3c07828 crossref_primary_10_3389_fendo_2023_1137456 crossref_primary_10_1016_j_addr_2021_113974 crossref_primary_10_3390_ijms26031362 crossref_primary_10_1016_j_carbpol_2025_123416 crossref_primary_10_1039_D3SC03932C crossref_primary_10_1016_j_biopha_2023_115513 crossref_primary_10_20517_cdr_2024_164 crossref_primary_10_1002_adfm_202302054 crossref_primary_10_1002_EXP_20210238 crossref_primary_10_1038_s41419_024_06616_7 crossref_primary_10_1080_14728222_2023_2259096 crossref_primary_10_1007_s12672_025_01825_8 crossref_primary_10_1172_jci_insight_152815 crossref_primary_10_1016_j_bbadis_2022_166528 crossref_primary_10_3390_cancers14215224 crossref_primary_10_1016_j_ijpharm_2024_124860 crossref_primary_10_1016_j_xcrm_2024_101737 crossref_primary_10_1038_s41598_024_70422_6 crossref_primary_10_1021_acsmaterialslett_4c00758 crossref_primary_10_1128_msphere_00626_22 crossref_primary_10_34133_research_0477 crossref_primary_10_3390_cancers15030703 crossref_primary_10_1002_1878_0261_13140 crossref_primary_10_3389_fimmu_2022_1017990 crossref_primary_10_3390_cancers13061374 crossref_primary_10_1002_advs_202400611 crossref_primary_10_1016_j_biocel_2022_106309 crossref_primary_10_3390_ijms242115920 crossref_primary_10_3390_nu15204483 crossref_primary_10_1002_adfm_202312092 crossref_primary_10_3390_ph14101023 crossref_primary_10_12677_acm_2024_143903 crossref_primary_10_3390_cells12162068 crossref_primary_10_1186_s13046_025_03290_1 crossref_primary_10_1002_advs_202201478 crossref_primary_10_1002_anbr_202300061 crossref_primary_10_1016_j_semcancer_2021_09_003 crossref_primary_10_1021_acs_jproteome_4c00914 crossref_primary_10_1111_jcmm_18346 crossref_primary_10_1136_jitc_2024_009165 crossref_primary_10_1186_s40364_024_00677_8 crossref_primary_10_3389_fimmu_2022_959114 crossref_primary_10_3390_biom11081213 crossref_primary_10_1002_cam4_6073 crossref_primary_10_1002_wsbm_1585 crossref_primary_10_1016_j_celrep_2023_113067 crossref_primary_10_3390_nano12020288 crossref_primary_10_1177_15353702211014185 crossref_primary_10_3389_fonc_2021_802592 crossref_primary_10_1021_acsabm_3c01251 crossref_primary_10_3390_cancers15030961 crossref_primary_10_1016_j_heliyon_2023_e14133 crossref_primary_10_3389_fonc_2022_1031706 crossref_primary_10_3390_biomedicines12010187 crossref_primary_10_1016_j_prp_2025_155811 crossref_primary_10_2147_IJN_S460387 crossref_primary_10_3389_fimmu_2023_1285540 crossref_primary_10_3390_biomedicines11061761 crossref_primary_10_1096_fj_202400725RR crossref_primary_10_1002_wnan_1848 crossref_primary_10_1007_s12013_023_01179_4 crossref_primary_10_3389_fimmu_2024_1409945 crossref_primary_10_2174_1871530322666220104103905 crossref_primary_10_1016_j_mcpro_2024_100792 crossref_primary_10_3389_fgene_2023_1155199 crossref_primary_10_1177_15330338241286755 crossref_primary_10_1002_adma_202210787 crossref_primary_10_1002_advs_202301071 crossref_primary_10_1016_j_arcmed_2022_11_011 crossref_primary_10_1016_j_trac_2022_116868 crossref_primary_10_1016_j_apsb_2023_12_003 crossref_primary_10_1038_s41467_023_38333_8 crossref_primary_10_1016_j_celrep_2021_110146 crossref_primary_10_1021_acsami_4c21725 crossref_primary_10_3389_fimmu_2021_697964 crossref_primary_10_3390_cells10112964 crossref_primary_10_1002_adhm_202401538 crossref_primary_10_1016_j_omtm_2024_101250 crossref_primary_10_1007_s12672_025_01803_0 crossref_primary_10_3389_fimmu_2024_1359914 crossref_primary_10_3390_ijms24032614 crossref_primary_10_47248_chp2502010003 crossref_primary_10_3389_fevo_2021_661583 crossref_primary_10_1089_ten_tec_2023_0199 crossref_primary_10_1186_s12951_024_02710_2 crossref_primary_10_1016_j_heliyon_2024_e27510 crossref_primary_10_1080_10255842_2023_2287418 crossref_primary_10_7759_cureus_69743 crossref_primary_10_1021_acsnano_4c07903 crossref_primary_10_1186_s12967_022_03780_2 crossref_primary_10_1016_j_micromeso_2021_110967 crossref_primary_10_1186_s12935_024_03511_1 crossref_primary_10_1016_j_bbcan_2021_188585 crossref_primary_10_3389_fcell_2021_680100 crossref_primary_10_3389_fmicb_2024_1287077 crossref_primary_10_3389_fphar_2024_1362675 crossref_primary_10_3390_cancers15215304 crossref_primary_10_3390_pharmaceutics14112388 crossref_primary_10_3389_fonc_2025_1532239 crossref_primary_10_1080_23808993_2021_1911639 crossref_primary_10_1515_nanoph_2021_0171 crossref_primary_10_1021_acsnano_1c03128 crossref_primary_10_1186_s12931_022_02227_y crossref_primary_10_1002_agt2_657 crossref_primary_10_1002_1878_0261_13695 crossref_primary_10_1016_j_intimp_2024_111876 crossref_primary_10_1111_jcmm_18393 crossref_primary_10_3892_ol_2023_14143 crossref_primary_10_1038_s41416_022_01886_4 crossref_primary_10_15541_jim20220435 crossref_primary_10_1016_j_neo_2024_101063 crossref_primary_10_1021_jacs_3c13165 crossref_primary_10_3389_fonc_2021_775363 crossref_primary_10_26599_CO_2024_9410004 crossref_primary_10_3390_cancers13030554 crossref_primary_10_1016_j_gendis_2024_101430 crossref_primary_10_1038_s44318_024_00283_2 crossref_primary_10_1016_j_semcancer_2021_08_003 crossref_primary_10_18632_aging_205189 crossref_primary_10_1038_s41598_024_80280_x crossref_primary_10_3389_fonc_2021_762184 crossref_primary_10_1016_j_jconrel_2022_01_009 crossref_primary_10_1016_j_phrs_2025_107674 crossref_primary_10_3390_biomedicines9091188 crossref_primary_10_3324_haematol_2021_279800 crossref_primary_10_1016_j_aohep_2024_101745 crossref_primary_10_3390_ijms232113128 crossref_primary_10_1007_s11033_025_10235_6 crossref_primary_10_3389_fimmu_2023_1122670 crossref_primary_10_3390_ijms24054524 crossref_primary_10_1186_s12943_024_01966_4 crossref_primary_10_1038_s41419_022_05041_y crossref_primary_10_3390_pharmaceutics14010018 crossref_primary_10_1016_j_apmt_2023_101868 crossref_primary_10_1186_s40824_023_00343_4 crossref_primary_10_1007_s13346_023_01512_7 crossref_primary_10_1371_journal_pone_0281378 crossref_primary_10_3389_fimmu_2023_1158964 crossref_primary_10_3390_cancers13112584 crossref_primary_10_1186_s13046_021_01953_3 crossref_primary_10_1186_s40001_023_01388_w crossref_primary_10_2147_PGPM_S458798 crossref_primary_10_3389_fcell_2023_1261749 crossref_primary_10_3389_fgene_2022_882794 crossref_primary_10_1021_acsomega_4c05209 crossref_primary_10_1021_acsanm_5c00589 crossref_primary_10_3389_fonc_2022_924290 crossref_primary_10_3390_cells11244026 crossref_primary_10_1038_s41420_024_02011_5 crossref_primary_10_1002_smll_202307310 crossref_primary_10_1007_s11060_024_04862_5 crossref_primary_10_1186_s12967_023_04281_6 crossref_primary_10_3389_fgene_2022_942785 crossref_primary_10_3390_ijms23158590 crossref_primary_10_1016_j_tranon_2022_101514 crossref_primary_10_3389_fcell_2025_1554312 crossref_primary_10_1002_adma_202412815 crossref_primary_10_1016_j_physrep_2023_07_006 crossref_primary_10_1038_s41467_023_39953_w crossref_primary_10_1002_advs_202202797 crossref_primary_10_1002_btm2_10651 crossref_primary_10_3390_cancers15133327 crossref_primary_10_3390_cells12202510 crossref_primary_10_1002_adma_202313389 crossref_primary_10_1038_s41586_021_04217_4 crossref_primary_10_1111_liv_16197 crossref_primary_10_1016_j_taap_2024_116975 crossref_primary_10_1155_2022_4355890 crossref_primary_10_1158_1535_7163_MCT_23_0158 crossref_primary_10_1002_advs_202411325 crossref_primary_10_3389_fimmu_2022_843077 crossref_primary_10_1016_j_tranon_2024_102095 crossref_primary_10_3389_fimmu_2024_1414376 crossref_primary_10_3389_fphar_2022_990665 crossref_primary_10_3390_cancers14102408 crossref_primary_10_1186_s12885_025_13834_5 crossref_primary_10_1088_1758_5090_ace0db crossref_primary_10_3390_biom12010132 crossref_primary_10_3389_fphar_2022_1091779 crossref_primary_10_3389_fonc_2022_871829 crossref_primary_10_3390_ijms24043667 crossref_primary_10_1038_s12276_023_01115_9 crossref_primary_10_3389_fimmu_2021_642842 crossref_primary_10_1016_j_compbiomed_2023_107151 |
| Cites_doi | 10.1016/j.cmet.2019.04.002 10.1016/S0006-291X(02)00271-1 10.1158/2326-6066.CIR-18-0749 10.1038/nm.3337 10.1016/j.cct.2016.10.004 10.1158/0008-5472.CAN-10-0522 10.1038/aps.2018.17 10.1126/science.aay9189 10.1016/j.ccell.2019.01.007 10.1038/nature07205 10.1158/2159-8290.CD-18-1398 10.1158/1078-0432.CCR-11-0641 10.1038/nrc3110 10.1038/ncb2048 10.1126/science.aaa6204 10.1074/jbc.M112.442939 10.1016/j.neuron.2015.01.026 10.1146/annurev-pharmtox-010818-021637 10.1016/j.tins.2016.10.002 10.1016/j.canlet.2015.07.039 10.1126/science.aad3018 10.4049/jimmunol.1900828 10.1002/ijc.22514 10.1038/nature16071 10.1016/j.jash.2018.03.008 10.1038/s41467-018-06641-z 10.1182/blood-2009-07-230508 10.1016/j.cell.2015.04.012 10.1016/j.cell.2005.10.041 10.1016/j.cell.2020.03.034 10.1001/jama.2013.6599 10.1158/1940-6207.CAPR-13-0337 10.1038/nrc.2017.77 10.1038/s41586-019-1576-6 10.1038/ncb2756 10.1016/j.cell.2019.11.013 10.1038/s41586-019-1563-y 10.1016/j.ccell.2017.06.009 10.1038/sj.bjc.6605450 10.1158/0008-5472.CAN-16-2400 10.1002/ijc.31783 10.1158/0008-5472.CAN-08-4859 10.1038/s41591-019-0750-6 10.18632/oncotarget.8694 10.1038/s41588-018-0318-2 10.1016/j.celrep.2019.11.079 10.1038/s41467-018-04724-5 10.1200/JCO.2011.35.5214 10.1038/s41568-018-0006-7 10.4049/jimmunol.1401710 10.1038/ni.3868 10.1046/j.1365-2362.2003.01152.x 10.1038/nrc.2016.84 10.1038/nrc1187 10.1242/jcs.116392 10.1172/JCI121985 10.1126/sciadv.aax6040 10.1186/s13063-019-3904-4 10.3389/fimmu.2019.00168 10.1158/2326-6066.CIR-14-0133 10.1002/cncr.24396 10.1158/1535-7163.MCT-17-0927 10.1016/j.stem.2015.02.015 10.1016/j.tcb.2014.06.001 10.1007/s00432-019-02902-6 10.1126/science.aau0447 10.1038/nrc3978 10.1038/s41416-019-0627-y 10.1038/s41568-019-0237-2 10.1016/j.trecan.2018.01.003 10.1016/j.bbcan.2020.188340 10.1093/brain/awy231 10.1016/S0140-6736(11)61049-0 10.1038/s41401-018-0014-x 10.7150/ijbs.3.328 10.1016/j.cell.2017.04.014 10.1016/j.imlet.2019.03.006 10.3402/jev.v4.27066 10.1158/0008-5472.CAN-17-3719 10.1016/j.phrs.2020.104683 10.1016/j.trecan.2019.09.007 10.1074/jbc.M109.041152 10.1186/s13058-018-1066-z 10.1016/j.cellimm.2017.12.003 10.1158/2326-6066.CIR-16-0103 10.1038/s41586-020-1998-1 10.1158/1078-0432.CCR-07-4362 10.1002/pros.23454 10.1016/j.bbcan.2019.01.003 10.1002/ijc.23818 10.1182/bloodadvances.2018026161 10.1002/ijc.32343 10.1038/sj.bjc.6603962 10.1371/journal.pone.0019246 10.1158/0008-5472.CAN-14-3180 10.1016/j.ccell.2019.03.007 10.1007/978-3-319-77736-8_2 10.1007/978-3-030-35727-6_10 10.1158/1078-0432.CCR-05-0108 10.1016/j.immuni.2019.06.025 10.1146/annurev-bioeng-071516-044546 10.1073/pnas.0911515107 10.1089/thy.2017.0550 10.1016/j.trecan.2019.12.008 10.1073/pnas.1804000116 10.1016/j.semcdb.2019.05.010 10.1172/JCI129502 10.18632/oncotarget.11263 10.1093/jnci/djy144 10.1016/j.trecan.2018.10.002 10.1007/s00262-018-2243-8 10.1016/j.jacc.2006.07.052 10.1002/cncr.29392 10.1038/343425a0 10.1016/j.ccell.2017.10.003 10.1038/nm.2492 10.1073/pnas.95.20.11715 10.1038/s41467-019-14052-x 10.4161/cc.20717 10.1001/jama.2014.8845 10.1158/2159-8290.CD-18-1489 10.3109/08820139.2012.685538 10.1038/s41591-020-0805-8 10.18632/oncotarget.2012 10.1038/nrd.2018.168 10.1158/0008-5472.CAN-18-3726 10.1111/j.1582-4934.2009.00994.x 10.1158/1078-0432.CCR-11-0607 10.1085/jgp.8.6.519 10.1016/j.pharmthera.2017.10.012 10.1016/j.trecan.2018.03.005 10.1056/NEJMoa1500596 10.1038/nrm.2017.87 10.1001/jamainternmed.2015.0289 10.1093/jnci/djk132 10.1016/j.canlet.2020.05.005 10.1126/science.aal5240 10.1200/JCO.2010.30.5037 10.1097/FJC.0000000000000085 10.1038/s41416-019-0725-x 10.1007/s00401-016-1583-8 10.1038/nature18268 10.1146/annurev-cancerbio-030419-033349 10.1002/pon.3233 10.3390/jcm7090264 10.1016/j.cell.2015.08.015 10.1200/JCO.2012.43.9190 10.1038/s41586-019-1564-x 10.1038/nrc3245 10.1016/j.ccell.2019.04.001 10.1146/annurev-cancerbio-050216-034431 10.18632/oncotarget.12833 10.1083/jcb.201102147 10.1158/1078-0432.CCR-05-0436 10.1016/j.jacc.2018.02.049 10.18632/oncotarget.18029 10.1016/j.trecan.2019.05.009 10.1172/JCI69600 10.1126/science.aaf2403 10.1016/j.tips.2017.05.002 10.1016/j.cmet.2016.12.018 10.1002/ijc.30717 10.1038/s41598-018-35103-1 10.1158/1078-0432.CCR-14-3368 10.1016/j.bcp.2018.05.013 10.1038/s41591-018-0014-x 10.1016/j.ccell.2019.08.007 10.1038/nrc.2016.71 10.1016/j.cell.2011.02.013 10.1034/j.1600-0714.2003.00128.x 10.1016/S1937-6448(09)75004-X 10.1038/modpathol.2017.156 10.3389/fimmu.2018.00164 10.1146/annurev-cancerbio-030419-033556 10.1016/j.trecan.2017.06.007 10.1200/JCO.2016.71.8981 10.1007/s10552-016-0804-8 10.1053/j.gastro.2018.04.010 10.1016/j.immuni.2018.03.023 10.1016/j.semcancer.2015.09.001 10.1007/s12032-019-1329-2 10.1016/j.immuni.2012.10.020 10.1158/0008-5472.CAN-10-4316 10.1038/nature12626 10.1172/JCI133115 10.3389/fcvm.2020.00026 10.3389/fonc.2019.01556 10.1074/jbc.M001914200 10.1200/JCO.18.00636 10.1038/s41568-019-0238-1 10.1126/science.1236361 10.1038/nature13490 10.1038/s41577-019-0259-8 10.4049/jimmunol.1701752 10.1038/s41586-019-0977-x 10.1016/j.biopha.2017.08.085 10.4049/jimmunol.1900594 10.1016/j.canlet.2013.08.029 10.1172/JCI120855 10.1038/nrc.2016.38 10.1073/pnas.1911951117 10.1073/pnas.1003428107 10.1158/2326-6066.CIR-17-0655 10.1016/j.cell.2020.02.042 10.1111/j.1349-7006.2012.02206.x 10.1016/j.trecan.2016.10.016 10.1016/S1535-6108(03)00310-6 10.1038/s41467-018-04987-y 10.1038/s43018-019-0018-6 10.1038/d41586-020-00314-y 10.1158/0008-5472.CAN-13-0080 10.3390/ijms20040840 10.1038/s41586-020-1996-3 10.1038/s41572-018-0055-y 10.1016/j.cell.2020.04.055 10.1016/j.phrs.2017.07.013 10.1016/j.tranon.2018.02.012 10.1245/s10434-008-9890-5 10.1080/15384101.2016.1191706 10.1126/science.aau6977 10.1016/j.molcel.2018.07.030 10.1146/annurev-physiol-021119-034627 10.1089/ars.2007.1674 10.1186/2049-3002-1-23 10.1001/jamanetworkopen.2019.0185 10.1016/j.cell.2006.11.001 10.1084/jem.20192282 10.1016/j.semcancer.2013.12.007 10.1016/j.semcancer.2013.08.009 10.1038/srep18673 10.1146/annurev-cancerbio-030419-033333 10.3389/fimmu.2016.00052 10.1038/s41587-019-0392-8 10.1016/j.canlet.2016.07.037 10.1016/j.trecan.2020.01.004 10.1016/j.semcancer.2020.01.003 10.1155/2018/6380643 10.1101/2019.12.30.890517 10.1016/j.semcancer.2019.06.021 10.1158/0008-5472.CAN-18-0747 10.3322/caac.21499 10.3390/cancers11081191 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2020 The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2020 – notice: The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7T5 7X7 7XB 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ H94 HCIFZ K9. LK8 M0S M7P PHGZM PHGZT PIMPY PKEHL PQEST PQGLB PQQKQ PQUKI PRINS 7X8 5PM |
| DOI | 10.1038/s41392-020-00280-x |
| DatabaseName | SpringerOpen CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Immunology Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni) Biological Science Database ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Biological Science Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic CrossRef Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Anatomy & Physiology |
| EISSN | 2059-3635 |
| ExternalDocumentID | PMC7447642 32843638 10_1038_s41392_020_00280_x |
| Genre | Research Support, Non-U.S. Gov't Journal Article Review |
| GrantInformation_xml | – fundername: 12th Undergraduate Training Program for Innova- tion of Shanghai Jiao Tong University School of Medicine – fundername: ; |
| GroupedDBID | 0R~ 3V. 5VS 7X7 8FI 8FJ AAJSJ ABUWG ACGFS ACSMW ADBBV AFKRA AJTQC ALMA_UNASSIGNED_HOLDINGS AOIJS BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI C6C CCPQU EBLON EBS EJD EMOBN FYUFA GROUPED_DOAJ HCIFZ HMCUK HYE M7P NAO OK1 PIMPY PQQKQ PROAC RNT RPM SNYQT UKHRP AASML AAYXX CITATION PHGZM PHGZT CGR CUY CVF ECM EIF NPM 7T5 7XB 8FE 8FH 8FK AARCD AZQEC DWQXO GNUQQ H94 K9. LK8 PKEHL PQEST PQGLB PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c540t-b5b5f326a3e4d05415c82b8f9d1e637a875bf03e32713c4c8d87e8606eac854a3 |
| IEDL.DBID | 7X7 |
| ISSN | 2059-3635 2095-9907 |
| IngestDate | Thu Aug 21 14:31:01 EDT 2025 Thu Jul 10 20:31:37 EDT 2025 Wed Aug 13 08:40:08 EDT 2025 Mon Jul 21 05:13:47 EDT 2025 Thu Apr 24 23:04:14 EDT 2025 Tue Jul 01 03:15:13 EDT 2025 Fri Feb 21 02:39:13 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c540t-b5b5f326a3e4d05415c82b8f9d1e637a875bf03e32713c4c8d87e8606eac854a3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0001-8011-2405 |
| OpenAccessLink | https://www.proquest.com/docview/2436973745?pq-origsite=%requestingapplication% |
| PMID | 32843638 |
| PQID | 2436973745 |
| PQPubID | 2041911 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7447642 proquest_miscellaneous_2437401587 proquest_journals_2436973745 pubmed_primary_32843638 crossref_primary_10_1038_s41392_020_00280_x crossref_citationtrail_10_1038_s41392_020_00280_x springer_journals_10_1038_s41392_020_00280_x |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2020-08-25 |
| PublicationDateYYYYMMDD | 2020-08-25 |
| PublicationDate_xml | – month: 08 year: 2020 text: 2020-08-25 day: 25 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Signal transduction and targeted therapy |
| PublicationTitleAbbrev | Sig Transduct Target Ther |
| PublicationTitleAlternate | Signal Transduct Target Ther |
| PublicationYear | 2020 |
| Publisher | Nature Publishing Group UK Nature Publishing Group |
| Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group |
| References | Ma (CR96) 2019; 30 Gilkes (CR142) 2013; 288 Inbar (CR146) 2011; 6 Scharping (CR226) 2017; 5 Harris, Beebe-Donk, Alshafie (CR177) 2007; 3 Vaughan (CR165) 2016; 27 Touyz, Herrmann, Herrmann (CR207) 2018; 12 Monje (CR109) 2020; 181 Ma (CR51) 2019; 36 Laplane (CR5) 2019; 145 Hsu, Li (CR174) 2002; 293 Amit (CR114) 2020; 578 Bhandari (CR49) 2020; 11 Sonveaux (CR101) 2008; 118 Chang (CR217) 2018; 11 Smith, Hodges (CR249) 2019; 5 Jobling (CR31) 2015; 75 Pan (CR63) 2019; 179 Watkins (CR195) 2015; 121 Elia (CR85) 2019; 568 Lu, Weaver, Werb (CR134) 2012; 196 Chalabi (CR186) 2020; 26 Altman, Stine, Dang (CR82) 2016; 16 CR172 Xiong (CR133) 2020; 117 Webb, Chimenti, Jacobson, Barber (CR99) 2011; 11 Calvo (CR131) 2013; 15 Cardinale, Iacopo, Cipolla (CR204) 2020; 7 Thorsson (CR15) 2018; 48 Vermeulen (CR130) 2010; 12 Tang (CR193) 2013; 23 Corbet, Feron (CR24) 2017; 17 Hernandez-Diaz, Rodriguez (CR178) 2007; 120 Gupta, Massague (CR62) 2006; 127 Osswald (CR120) 2015; 528 Hamy (CR191) 2019; 37 Zeng (CR123) 2019; 573 Liu (CR34) 2018; 78 Mehibel (CR235) 2018; 8 Xavier (CR244) 2020; 6 Achrol (CR124) 2019; 5 Sorensen (CR209) 2013; 31 Chiche, Brahimi-Horn, Pouyssegur (CR100) 2010; 14 Verbaanderd, Meheus, Huys, Pantziarka (CR160) 2017; 3 Friebel (CR71) 2000; 181 Lu (CR167) 2008; 14 Ros, Vermeulen (CR14) 2018; 4 Yanez-Mo (CR107) 2015; 4 Berglund (CR251) 2018; 9 Stahl (CR252) 2016; 353 Lavin (CR69) 2017; 169 Venkataramani (CR121) 2019; 573 Riesenberg (CR169) 2019; 203 Fischer (CR70) 2019; 9 Laughney (CR68) 2020; 26 Seliger (CR216) 2019; 144 Warburg, Wind, Negelein (CR77) 1927; 8 Li, Le (CR83) 2018; 1063 Klein-Goldberg, Maman, Witz (CR42) 2014; 352 Semenza (CR138) 2008; 118 Quail (CR158) 2016; 352 Qiu (CR13) 2017; 38 Costa, Scholer-Dahirel, Mechta-Grigoriou (CR93) 2014; 25 Faulkner (CR30) 2019; 9 Liao, Tan, Zhu, Tan (CR38) 2019; 343 Panciera, Azzolin, Cordenonsi, Piccolo (CR128) 2017; 18 Schulz (CR116) 2016; 132 Groen (CR188) 2011; 29 Zelenay (CR183) 2015; 162 Liebig (CR110) 2009; 115 Kurelac (CR213) 2020; 98 Lamonte (CR103) 2013; 1 Boedtkjer, Pedersen (CR23) 2020; 82 Tamura (CR137) 2019; 37 Qu, Boelte, Lin (CR91) 2012; 41 Mahmoud (CR220) 2011; 29 Maman, Witz (CR3) 2018; 18 Angelin (CR79) 2017; 25 Liu (CR232) 2016; 7 Larsen (CR233) 2017; 35 Lindgren (CR197) 2013; 22 Kutner (CR238) 2015; 175 Balkwill, Capasso, Hagemann (CR7) 2012; 125 Cole (CR29) 2015; 15 Horikawa (CR136) 2020; 122 Pushpakom (CR159) 2019; 18 Benish (CR194) 2008; 15 Kobayashi (CR237) 2015; 21 Chandel (CR87) 1998; 95 Qiao (CR198) 2018; 9 Kim (CR192) 2018; 52 Nejman (CR247) 2020; 368 Tseng (CR212) 2018; 7 Mohammadpour (CR143) 2019; 129 Sung (CR162) 2019; 69 Li (CR150) 2020; 220 Gillies, Pilot, Marunaka, Fais (CR105) 2019; 1871 Burn (CR180) 2011; 378 Deng (CR11) 2019; 9 Saloman, Albers, Rhim, Davis (CR26) 2016; 39 Lopez-Soto, Gonzalez, Smyth, Galluzzi (CR67) 2017; 32 Joyce, Fearon (CR54) 2015; 348 Nagelkerke, Bussink, Rowan, Span (CR127) 2015; 35 Palazon (CR45) 2017; 32 CR16 CR12 Goldstein, Brown (CR231) 1990; 343 Hui, Chen (CR41) 2015; 368 Chappell, Payne, Rathmell (CR206) 2019; 129 Pyonteck (CR157) 2013; 19 Csiki (CR190) 2005; 11 Wang (CR205) 2017; 8 Wisdom (CR37) 2018; 9 Gharpure (CR98) 2018; 9 Pritchard (CR187) 2018; 154 Beckwitt, Brufsky, Oltvai, Wells (CR234) 2018; 20 Laplane (CR6) 2018; 4 Yamamoto (CR196) 2019; 20 Lau, Vander Heiden (CR18) 2020; 4 Johnson (CR170) 2019; 3 Fendt (CR223) 2013; 73 Sauvant (CR108) 2008; 123 Ribatti (CR46) 2016; 7 Hanahan, Weinberg (CR4) 2011; 144 Jansen (CR210) 2017; 141 Mantovani, Allavena, Sica, Balkwill (CR9) 2008; 454 Ackerman, Simon (CR17) 2014; 24 Khosravi (CR8) 2018; 6 Mazzio, Boukli, Rivera, Soliman (CR104) 2012; 103 Xu (CR229) 2018; 17 Ye (CR50) 2019; 2 Simon, Ludvigsson (CR181) 2020; 382 Sivalingam (CR227) 2020; 122 Zahalka, Frenette (CR28) 2020; 20 Nonomura (CR56) 2007; 97 Nishihara (CR163) 2013; 309 Moncada (CR250) 2020; 38 Valiente (CR65) 2018; 4 Sun, Luo, Jiang, Duan (CR39) 2018; 39 Colegio (CR78) 2014; 513 Qiao (CR200) 2019; 68 Binnewies (CR155) 2018; 24 Ceelen (CR66) 2020; 6 Todoric, Karin (CR10) 2019; 35 Cole, Sood (CR148) 2012; 18 Mandal (CR185) 2019; 364 Chandel (CR88) 2000; 275 Schito, Semenza (CR43) 2016; 2 Taube (CR156) 2018; 31 Ayad, Weaver (CR32) 2020; 578 Magnon (CR25) 2013; 341 Sleire (CR161) 2017; 124 Deepak (CR141) 2020; 153 Cooper, Giancotti (CR135) 2019; 35 Jacobs (CR179) 2007; 99 Paget (CR1) 1989; 8 Dannenberg, Subbaramaiah (CR182) 2003; 4 Fukumura (CR47) 2001; 61 Maj (CR94) 2017; 18 Kovacs (CR243) 2020; 1225 Venkatesh (CR118) 2015; 161 Tebbe (CR224) 2014; 5 Cho (CR215) 2018; 28 Cole (CR149) 2010; 107 Kalay (CR202) 2006; 48 Coyle (CR166) 2016; 51 Paolini (CR22) 2020; 8 Avila (CR201) 2018; 71 Ivashkiv (CR140) 2020; 20 Semenza (CR154) 2019; 59 Ribatti, Crivellato (CR59) 2009; 275 Devalaraja (CR242) 2020; 180 Bhandari (CR52) 2019; 51 Ulrich, de Juan Pardo, Kumar (CR36) 2009; 69 Liu (CR176) 2019; 40 Thrane (CR253) 2018; 78 Romero-Garcia, Moreno-Altamirano, Prado-Garcia, Sanchez-Garcia (CR20) 2016; 7 Shurin, Shurin, Zlotnikov, Bunimovich (CR27) 2020; 204 Parks, Mueller-Klieser, Pouyssegur (CR74) 2020; 4 Semenza, Wang (CR44) 1992; 12 Lucotti (CR171) 2019; 129 Capparelli (CR89) 2012; 11 Bonaventura (CR53) 2019; 10 McCarty, Whitaker (CR151) 2010; 15 Cheung (CR214) 2019; 111 Dassler-Plenker, Kuttner, Egeblad (CR248) 2020; 1873 Jean Wrobel (CR199) 2016; 7 Peppicelli (CR102) 2016; 15 You (CR111) 2020; 6 Talarico (CR222) 2016; 6 Inigo-Marco, Alonso (CR144) 2019; 129 Bullman (CR245) 2017; 358 Ribatti (CR57) 2003; 33 Le (CR184) 2015; 372 Henry (CR175) 2017; 77 Clendening (CR236) 2010; 115 Altorki (CR189) 2005; 11 Nakazawa, Keith, Simon (CR19) 2016; 16 Hensley, Wasti, DeBerardinis (CR81) 2013; 123 CR72 Pusceddu (CR218) 2018; 155 Bansal (CR203) 2019; 5 Junttila, de Sauvage (CR132) 2013; 501 Chang (CR60) 2011; 17 Shi (CR246) 2020; 217 Amit, Na’ara, Gil (CR115) 2016; 16 Sena (CR92) 2013; 38 Buffa, Harris, West, Miller (CR48) 2010; 102 Yang, Venneti, Nagrath (CR84) 2017; 19 Hunt (CR80) 2007; 9 Voelker (CR239) 2014; 312 CR86 Plaks, Kong, Werb (CR129) 2015; 16 Wimberly (CR221) 2015; 3 Kalluri, LeBleu (CR2) 2020; 367 Cha (CR219) 2018; 71 Dewhirst (CR241) 1996; 27 Ligtenberg (CR95) 2016; 196 Hanoun, Maryanovich, Arnal-Estape, Frenette (CR112) 2015; 86 Roma-Rodrigues, Mendes, Baptista, Fernandes (CR152) 2019; 20 Olkhanud (CR64) 2011; 71 Parolini (CR106) 2009; 284 Iamaroon (CR58) 2003; 32 Zhang (CR139) 2019; 145 Sahai (CR61) 2020; 20 Park (CR35) 2020; 578 Galland (CR240) 2020; 484 Mohammadpour (CR147) 2018; 200 Weinberg (CR90) 2010; 107 Fridman, Pages, Sautes-Fridman, Galon (CR55) 2012; 12 Nieman (CR97) 2011; 17 Venkatesh (CR122) 2019; 573 Chen (CR126) 2016; 533 Bassez (CR211) 2018; 141 Chen (CR228) 2019; 41 Yue, Yang, DiPaola, Tan (CR168) 2014; 7 Peck, Schulze (CR75) 2019; 5 Mao (CR125) 2016; 381 Elgendy (CR230) 2019; 35 Mao (CR73) 2018; 183 Coarfa (CR113) 2018; 78 Hart (CR225) 2019; 29 Sloan (CR145) 2010; 70 Semenza (CR153) 2003; 3 Vaupel, Kallinowski, Okunieff (CR76) 1989; 49 Gillespie, Monje (CR117) 2020; 4 Gilligan (CR173) 2019; 116 Garcia-Canaveras, Chen, Rabinowitz (CR21) 2019; 79 Leight, Drain, Weaver (CR33) 2017; 1 Greten, Grivennikov (CR40) 2019; 51 Stati (CR208) 2014; 64 Corsello (CR254) 2020; 1 Ma (CR164) 2017; 95 Katayama (CR119) 2006; 124 PB Olkhanud (280_CR64) 2011; 71 XY Mao (280_CR125) 2016; 381 JH Cha (280_CR219) 2018; 71 S Deng (280_CR11) 2019; 9 XZ Ma (280_CR96) 2019; 30 DF Quail (280_CR158) 2016; 352 C Verbaanderd (280_CR160) 2017; 3 GV Sorensen (280_CR209) 2013; 31 JW Clendening (280_CR236) 2010; 115 S Bullman (280_CR245) 2017; 358 A Costa (280_CR93) 2014; 25 KM Gharpure (280_CR98) 2018; 9 GL Semenza (280_CR44) 1992; 12 I Elia (280_CR85) 2019; 568 E Friebel (280_CR71) 2000; 181 L Jean Wrobel (280_CR199) 2016; 7 GL Semenza (280_CR153) 2003; 3 L Schito (280_CR43) 2016; 2 N Nonomura (280_CR56) 2007; 97 J Cooper (280_CR135) 2019; 35 MM Gilligan (280_CR173) 2019; 116 V Venkataramani (280_CR121) 2019; 573 B Peck (280_CR75) 2019; 5 P Sonveaux (280_CR101) 2008; 118 Q Chen (280_CR126) 2016; 533 AJ Dannenberg (280_CR182) 2003; 4 R Kalluri (280_CR2) 2020; 367 S Maman (280_CR3) 2018; 18 FM Buffa (280_CR48) 2010; 102 SM Pyonteck (280_CR157) 2013; 19 JS Kutner (280_CR238) 2015; 175 FR Greten (280_CR40) 2019; 51 T Maj (280_CR94) 2017; 18 M Monje (280_CR109) 2020; 181 280_CR72 I Parolini (280_CR106) 2009; 284 Y Kobayashi (280_CR237) 2015; 21 GX Qiao (280_CR198) 2018; 9 Z Liao (280_CR38) 2019; 343 GP Gupta (280_CR62) 2006; 127 D Hanahan (280_CR4) 2011; 144 P Jobling (280_CR31) 2015; 75 AS Hamy (280_CR191) 2019; 37 M Hanoun (280_CR112) 2015; 86 Y Li (280_CR150) 2020; 220 GM Fischer (280_CR70) 2019; 9 V Bhandari (280_CR52) 2019; 51 SK Parks (280_CR74) 2020; 4 LB Ivashkiv (280_CR140) 2020; 20 LA Sena (280_CR92) 2013; 38 S Romero-Garcia (280_CR20) 2016; 7 PF Lu (280_CR134) 2012; 196 NE Scharping (280_CR226) 2017; 5 S Devalaraja (280_CR242) 2020; 180 M Chalabi (280_CR186) 2020; 26 M Amit (280_CR115) 2016; 16 C Coarfa (280_CR113) 2018; 78 S Pushpakom (280_CR159) 2019; 18 ME Lindgren (280_CR197) 2013; 22 C Pan (280_CR63) 2019; 179 SB Larsen (280_CR233) 2017; 35 GL Semenza (280_CR138) 2008; 118 L Yang (280_CR84) 2017; 19 A Iamaroon (280_CR58) 2003; 32 NK Altorki (280_CR189) 2005; 11 PC Hart (280_CR225) 2019; 29 M Benish (280_CR194) 2008; 15 I Inigo-Marco (280_CR144) 2019; 129 T Stati (280_CR208) 2014; 64 KGK Deepak (280_CR141) 2020; 153 V Bhandari (280_CR49) 2020; 11 L Vermeulen (280_CR130) 2010; 12 J Todoric (280_CR10) 2019; 35 AS Achrol (280_CR124) 2019; 5 L Jansen (280_CR210) 2017; 141 R Moncada (280_CR250) 2020; 38 280_CR16 JB Xavier (280_CR244) 2020; 6 S Hernandez-Diaz (280_CR178) 2007; 120 H Sung (280_CR162) 2019; 69 S Ye (280_CR50) 2019; 2 G Lamonte (280_CR103) 2013; 1 E Berglund (280_CR251) 2018; 9 L Laplane (280_CR5) 2019; 145 CS Hsu (280_CR174) 2002; 293 280_CR12 W Ceelen (280_CR66) 2020; 6 L Laplane (280_CR6) 2018; 4 LC Ma (280_CR51) 2019; 36 K Thrane (280_CR253) 2018; 78 X Zhang (280_CR139) 2019; 145 W Yue (280_CR168) 2014; 7 EA Mazzio (280_CR104) 2012; 103 Y Lavin (280_CR69) 2017; 169 S Galland (280_CR240) 2020; 484 D Nejman (280_CR247) 2020; 368 C Corbet (280_CR24) 2017; 17 A Nagelkerke (280_CR127) 2015; 35 SM Fendt (280_CR223) 2013; 73 AN Lau (280_CR18) 2020; 4 KM Nieman (280_CR97) 2011; 17 JC Garcia-Canaveras (280_CR21) 2019; 79 S Paget (280_CR1) 1989; 8 WS Henry (280_CR175) 2017; 77 I Csiki (280_CR190) 2005; 11 JL Watkins (280_CR195) 2015; 121 MR Junttila (280_CR132) 2013; 501 ML Lu (280_CR167) 2008; 14 V Plaks (280_CR129) 2015; 16 C Sauvant (280_CR108) 2008; 123 S Lucotti (280_CR171) 2019; 129 HS Venkatesh (280_CR122) 2019; 573 Q Zeng (280_CR123) 2019; 573 JL Saloman (280_CR26) 2016; 39 P Vaupel (280_CR76) 1989; 49 T Kovacs (280_CR243) 2020; 1225 CT Hensley (280_CR81) 2013; 123 CH Tseng (280_CR212) 2018; 7 PL Stahl (280_CR252) 2016; 353 JL Leight (280_CR33) 2017; 1 E Sahai (280_CR61) 2020; 20 S Zelenay (280_CR183) 2015; 162 J Tang (280_CR193) 2013; 23 C Liebig (280_CR110) 2009; 115 SW Cole (280_CR148) 2012; 18 M Amit (280_CR114) 2020; 578 P Qu (280_CR91) 2012; 41 S Faulkner (280_CR30) 2019; 9 D Fukumura (280_CR47) 2001; 61 H Mohammadpour (280_CR143) 2019; 129 DT Le (280_CR184) 2015; 372 R Nishihara (280_CR163) 2013; 309 GZ Qiu (280_CR13) 2017; 38 MW Dewhirst (280_CR241) 1996; 27 D Cardinale (280_CR204) 2020; 7 R Tamura (280_CR137) 2019; 37 YY Shi (280_CR246) 2020; 217 KS Cheung (280_CR214) 2019; 111 W Sun (280_CR39) 2018; 39 BJ Altman (280_CR82) 2016; 16 L Sleire (280_CR161) 2017; 124 JC Chappell (280_CR206) 2019; 129 H Yamamoto (280_CR196) 2019; 20 P Bonaventura (280_CR53) 2019; 10 SM Corsello (280_CR254) 2020; 1 S Gillespie (280_CR117) 2020; 4 SW Cole (280_CR29) 2015; 15 RJ Gillies (280_CR105) 2019; 1871 BA Webb (280_CR99) 2011; 11 YY Liu (280_CR34) 2018; 78 MS Avila (280_CR201) 2018; 71 M Elgendy (280_CR230) 2019; 35 J Burn (280_CR180) 2011; 378 N Kalay (280_CR202) 2006; 48 MR Shurin (280_CR27) 2020; 204 J Ma (280_CR164) 2017; 95 M Mehibel (280_CR235) 2018; 8 D Ribatti (280_CR46) 2016; 7 NS Chandel (280_CR87) 1998; 95 DM Gilkes (280_CR142) 2013; 288 A Klein-Goldberg (280_CR42) 2014; 352 EK Sloan (280_CR145) 2010; 70 S Xu (280_CR229) 2018; 17 YT Chang (280_CR217) 2018; 11 LE Vaughan (280_CR165) 2016; 27 D Ackerman (280_CR17) 2014; 24 R Voelker (280_CR239) 2014; 312 JC Liu (280_CR232) 2016; 7 RM Touyz (280_CR207) 2018; 12 H Wimberly (280_CR221) 2015; 3 E Boedtkjer (280_CR23) 2020; 82 TG Simon (280_CR181) 2020; 382 JA Joyce (280_CR54) 2015; 348 EJ Jacobs (280_CR179) 2007; 99 G Qiao (280_CR200) 2019; 68 G Bassez (280_CR211) 2018; 141 TA Ulrich (280_CR36) 2009; 69 CH Beckwitt (280_CR234) 2018; 20 I Kurelac (280_CR213) 2020; 98 MF McCarty (280_CR151) 2010; 15 C Roma-Rodrigues (280_CR152) 2019; 20 RE Harris (280_CR177) 2007; 3 T Li (280_CR83) 2018; 1063 SMA Mahmoud (280_CR220) 2011; 29 JL Goldstein (280_CR231) 1990; 343 JS Park (280_CR35) 2020; 578 M Yanez-Mo (280_CR107) 2015; 4 FR Balkwill (280_CR7) 2012; 125 WH Fridman (280_CR55) 2012; 12 BP Riesenberg (280_CR169) 2019; 203 280_CR172 A Palazon (280_CR45) 2017; 32 F Weinberg (280_CR90) 2010; 107 S Inbar (280_CR146) 2011; 6 NS Chandel (280_CR88) 2000; 275 J Chiche (280_CR100) 2010; 14 C Tebbe (280_CR224) 2014; 5 G Chen (280_CR228) 2019; 41 G Talarico (280_CR222) 2016; 6 M Osswald (280_CR120) 2015; 528 N Horikawa (280_CR136) 2020; 122 HS Venkatesh (280_CR118) 2015; 161 JC Wang (280_CR205) 2017; 8 C Capparelli (280_CR89) 2012; 11 T Panciera (280_CR128) 2017; 18 GL Semenza (280_CR154) 2019; 59 YY Cho (280_CR215) 2018; 28 EA Smith (280_CR249) 2019; 5 280_CR86 Y Katayama (280_CR119) 2006; 124 R Mandal (280_CR185) 2019; 364 O Warburg (280_CR77) 1927; 8 A Angelin (280_CR79) 2017; 25 MA Ligtenberg (280_CR95) 2016; 196 AM Laughney (280_CR68) 2020; 26 N Bansal (280_CR203) 2019; 5 N Khosravi (280_CR8) 2018; 6 OR Colegio (280_CR78) 2014; 513 YX Liu (280_CR176) 2019; 40 HJ Groen (280_CR188) 2011; 29 MS Nakazawa (280_CR19) 2016; 16 AH Zahalka (280_CR28) 2020; 20 JM Taube (280_CR156) 2018; 31 C Magnon (280_CR25) 2013; 341 A Lopez-Soto (280_CR67) 2017; 32 TK Hunt (280_CR80) 2007; 9 L Hui (280_CR41) 2015; 368 R Pritchard (280_CR187) 2018; 154 L Paolini (280_CR22) 2020; 8 KM Wisdom (280_CR37) 2018; 9 V Thorsson (280_CR15) 2018; 48 A Schulz (280_CR116) 2016; 132 NME Ayad (280_CR32) 2020; 578 SW Cole (280_CR149) 2010; 107 C Seliger (280_CR216) 2019; 144 F Calvo (280_CR131) 2013; 15 D Ribatti (280_CR57) 2003; 33 D Ribatti (280_CR59) 2009; 275 H You (280_CR111) 2020; 6 H Mohammadpour (280_CR147) 2018; 200 G Xiong (280_CR133) 2020; 117 S Peppicelli (280_CR102) 2016; 15 C Coyle (280_CR166) 2016; 51 XR Ros (280_CR14) 2018; 4 A Mantovani (280_CR9) 2008; 454 M Valiente (280_CR65) 2018; 4 S Pusceddu (280_CR218) 2018; 155 M Binnewies (280_CR155) 2018; 24 J Kim (280_CR192) 2018; 52 DZ Chang (280_CR60) 2011; 17 KE Johnson (280_CR170) 2019; 3 XY Mao (280_CR73) 2018; 183 VN Sivalingam (280_CR227) 2020; 122 J Dassler-Plenker (280_CR248) 2020; 1873 |
| References_xml | – volume: 30 start-page: 143 year: 2019 end-page: 156.e5 ident: CR96 article-title: Cholesterol induces CD8(+) T cell exhaustion in the tumor microenvironment publication-title: Cell Metab. doi: 10.1016/j.cmet.2019.04.002 – volume: 293 start-page: 705 year: 2002 end-page: 709 ident: CR174 article-title: Aspirin potently inhibits oxidative DNA strand breaks: implications for cancer chemoprevention publication-title: Biochem. Biophys. Res. Commun. doi: 10.1016/S0006-291X(02)00271-1 – volume: 8 start-page: 383 year: 2020 end-page: 395 ident: CR22 article-title: Lactic acidosis together with GM-CSF and M-CSF induces human macrophages toward an inflammatory protumor phenotype publication-title: Cancer Immunol. Res. doi: 10.1158/2326-6066.CIR-18-0749 – volume: 19 start-page: 1264 year: 2013 end-page: 1272 ident: CR157 article-title: CSF-1R inhibition alters macrophage polarization and blocks glioma progression publication-title: Nat. Med. doi: 10.1038/nm.3337 – ident: CR16 – volume: 51 start-page: 56 year: 2016 end-page: 64 ident: CR166 article-title: ADD-ASPIRIN: a phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours publication-title: Contemp. Clin. Trials doi: 10.1016/j.cct.2016.10.004 – volume: 70 start-page: 7042 year: 2010 end-page: 7052 ident: CR145 article-title: The sympathetic nervous system induces a metastatic switch in primary breast cancer publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-10-0522 – volume: 39 start-page: 534 year: 2018 end-page: 541 ident: CR39 article-title: Tumor exosomes: a double-edged sword in cancer therapy publication-title: Acta Pharm. Sin. doi: 10.1038/aps.2018.17 – volume: 368 start-page: 973 year: 2020 end-page: 980 ident: CR247 article-title: The human tumor microbiome is composed of tumor type-specific intracellular bacteria publication-title: Science doi: 10.1126/science.aay9189 – volume: 35 start-page: 347 year: 2019 end-page: 367 ident: CR135 article-title: Integrin signaling in cancer: mechanotransduction, stemness, epithelial plasticity, and therapeutic resistance publication-title: Cancer Cell. doi: 10.1016/j.ccell.2019.01.007 – volume: 454 start-page: 436 year: 2008 end-page: 444 ident: CR9 article-title: Cancer-related inflammation publication-title: Nature doi: 10.1038/nature07205 – volume: 9 start-page: 702 year: 2019 end-page: 710 ident: CR30 article-title: Tumor neurobiology and the war of nerves in cancer publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-18-1398 – volume: 78 start-page: 5970 year: 2018 end-page: 5979 ident: CR253 article-title: Spatially Resolved Transcriptomics Enables Dissection of Genetic Heterogeneity in Stage III Cutaneous Malignant Melanoma publication-title: Cancer Res. – volume: 18 start-page: 1201 year: 2012 end-page: 1206 ident: CR148 article-title: Molecular pathways: beta-adrenergic signaling in cancer publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-11-0641 – volume: 12 start-page: 5447 year: 1992 end-page: 5454 ident: CR44 article-title: A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation publication-title: Mol. Cell Biol. – volume: 11 start-page: 671 year: 2011 end-page: 677 ident: CR99 article-title: Dysregulated pH: a perfect storm for cancer progression publication-title: Nat. Rev. Cancer doi: 10.1038/nrc3110 – volume: 12 start-page: 468 year: 2010 end-page: 476 ident: CR130 article-title: Wnt activity defines colon cancer stem cells and is regulated by the microenvironment publication-title: Nat. Cell Biol. doi: 10.1038/ncb2048 – volume: 348 start-page: 74 year: 2015 end-page: 80 ident: CR54 article-title: T cell exclusion, immune privilege, and the tumor microenvironment publication-title: Science doi: 10.1126/science.aaa6204 – volume: 15 start-page: 264 year: 2010 end-page: 272 ident: CR151 article-title: Manipulating tumor acidification as a cancer treatment strategy publication-title: Alter. Med. Rev. – volume: 288 start-page: 10819 year: 2013 end-page: 10829 ident: CR142 article-title: Hypoxia-inducible factor 1 (HIF-1) promotes extracellular matrix remodeling under hypoxic conditions by inducing P4HA1, P4HA2, and PLOD2 expression in fibroblasts publication-title: J. Biol. Chem. doi: 10.1074/jbc.M112.442939 – volume: 86 start-page: 360 year: 2015 end-page: 373 ident: CR112 article-title: Neural regulation of hematopoiesis, inflammation, and cancer publication-title: Neuron doi: 10.1016/j.neuron.2015.01.026 – volume: 59 start-page: 379 year: 2019 end-page: 403 ident: CR154 article-title: Pharmacologic targeting of hypoxia-inducible factors publication-title: Annu. Rev. Pharm. doi: 10.1146/annurev-pharmtox-010818-021637 – volume: 39 start-page: 880 year: 2016 end-page: 889 ident: CR26 article-title: Can stopping nerves, stop cancer? publication-title: Trends Neurosci. doi: 10.1016/j.tins.2016.10.002 – volume: 368 start-page: 7 year: 2015 end-page: 13 ident: CR41 article-title: Tumor microenvironment: sanctuary of the devil publication-title: Cancer Lett. doi: 10.1016/j.canlet.2015.07.039 – volume: 352 start-page: aad3018 year: 2016 ident: CR158 article-title: The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas publication-title: Science doi: 10.1126/science.aad3018 – volume: 41 start-page: 405 year: 2019 end-page: 414 ident: CR228 article-title: Metformin suppresses gastric cancer progression through calmodulinlike protein 3 secreted from tumorassociated fibroblasts publication-title: Oncol. Rep. – volume: 204 start-page: 280 year: 2020 end-page: 285 ident: CR27 article-title: The neuroimmune axis in the tumor microenvironment publication-title: J. Immunol. doi: 10.4049/jimmunol.1900828 – volume: 120 start-page: 1565 year: 2007 end-page: 1572 ident: CR178 article-title: Nonsteroidal anti-inflammatory drugs and risk of lung cancer publication-title: Int. J. Cancer doi: 10.1002/ijc.22514 – volume: 528 start-page: 93 year: 2015 end-page: 98 ident: CR120 article-title: Brain tumour cells interconnect to a functional and resistant network publication-title: Nature doi: 10.1038/nature16071 – volume: 12 start-page: 409 year: 2018 end-page: 425 ident: CR207 article-title: Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events publication-title: J. Am. Soc. Hypertens. doi: 10.1016/j.jash.2018.03.008 – volume: 9 year: 2018 ident: CR37 article-title: Matrix mechanical plasticity regulates cancer cell migration through confining microenvironments publication-title: Nat. Commun. doi: 10.1038/s41467-018-06641-z – volume: 115 start-page: 4787 year: 2010 end-page: 4797 ident: CR236 article-title: Exploiting the mevalonate pathway to distinguish statin-sensitive multiple myeloma publication-title: Blood doi: 10.1182/blood-2009-07-230508 – volume: 161 start-page: 803 year: 2015 end-page: 816 ident: CR118 article-title: Neuronal activity promotes glioma growth through neuroligin-3 secretion publication-title: Cell doi: 10.1016/j.cell.2015.04.012 – volume: 118 start-page: 3930 year: 2008 end-page: 3942 ident: CR101 article-title: Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice publication-title: J. Clin. Investig. – volume: 124 start-page: 407 year: 2006 end-page: 421 ident: CR119 article-title: Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow publication-title: Cell doi: 10.1016/j.cell.2005.10.041 – volume: 181 start-page: 219 year: 2020 end-page: 222 ident: CR109 article-title: Roadmap for the emerging field of cancer neuroscience publication-title: Cell doi: 10.1016/j.cell.2020.03.034 – volume: 309 start-page: 2563 year: 2013 end-page: 2571 ident: CR163 article-title: Aspirin use and risk of colorectal cancer according to BRAF mutation status publication-title: JAMA doi: 10.1001/jama.2013.6599 – volume: 7 start-page: 388 year: 2014 end-page: 397 ident: CR168 article-title: Repurposing of metformin and aspirin by targeting AMPK-mTOR and inflammation for pancreatic cancer prevention and treatment publication-title: Cancer Prev. Res. (Philos.) doi: 10.1158/1940-6207.CAPR-13-0337 – volume: 17 start-page: 577 year: 2017 end-page: 593 ident: CR24 article-title: Tumour acidosis: from the passenger to the driver’s seat publication-title: Nat. Rev. Cancer doi: 10.1038/nrc.2017.77 – volume: 573 start-page: 526 year: 2019 end-page: 531 ident: CR123 article-title: Synaptic proximity enables NMDAR signalling to promote brain metastasis publication-title: Nature doi: 10.1038/s41586-019-1576-6 – volume: 15 start-page: 637 year: 2013 end-page: 646 ident: CR131 article-title: Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts publication-title: Nat. Cell Biol. doi: 10.1038/ncb2756 – volume: 179 start-page: 1661 year: 2019 end-page: 1676.e19 ident: CR63 article-title: Deep learning reveals cancer metastasis and therapeutic antibody targeting in the entire body publication-title: Cell doi: 10.1016/j.cell.2019.11.013 – ident: CR86 – volume: 573 start-page: 539 year: 2019 end-page: 545 ident: CR122 article-title: Electrical and synaptic integration of glioma into neural circuits publication-title: Nature doi: 10.1038/s41586-019-1563-y – volume: 32 start-page: 135 year: 2017 end-page: 154 ident: CR67 article-title: Control of metastasis by NK cells publication-title: Cancer Cell. doi: 10.1016/j.ccell.2017.06.009 – volume: 102 start-page: 428 year: 2010 end-page: 435 ident: CR48 article-title: Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene publication-title: Br. J. Cancer doi: 10.1038/sj.bjc.6605450 – volume: 77 start-page: 790 year: 2017 end-page: 801 ident: CR175 article-title: Aspirin suppresses growth in PI3K-mutant breast cancer by activating AMPK and Inhibiting mTORC1 signaling publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-16-2400 – volume: 144 start-page: 273 year: 2019 end-page: 280 ident: CR216 article-title: Use of metformin and survival of patients with high-grade glioma publication-title: Int. J. Cancer doi: 10.1002/ijc.31783 – volume: 69 start-page: 4167 year: 2009 end-page: 4174 ident: CR36 article-title: The mechanical rigidity of the extracellular matrix regulates the structure, motility, and proliferation of glioma cells publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-08-4859 – volume: 26 start-page: 259 year: 2020 end-page: 269 ident: CR68 article-title: Regenerative lineages and immune-mediated pruning in lung cancer metastasis publication-title: Nat. Med. doi: 10.1038/s41591-019-0750-6 – volume: 7 start-page: 46668 year: 2016 end-page: 46677 ident: CR46 article-title: Tumor refractoriness to anti-VEGF therapy publication-title: Oncotarget doi: 10.18632/oncotarget.8694 – volume: 51 start-page: 308 year: 2019 end-page: 318 ident: CR52 article-title: Molecular landmarks of tumor hypoxia across cancer types publication-title: Nat. Genet. doi: 10.1038/s41588-018-0318-2 – volume: 29 start-page: 4086 year: 2019 end-page: 4098 e4086 ident: CR225 article-title: Mesothelial cell HIF1alpha expression is metabolically downregulated by metformin to prevent oncogenic tumor-stromal crosstalk publication-title: Cell Rep. doi: 10.1016/j.celrep.2019.11.079 – volume: 9 year: 2018 ident: CR251 article-title: Spatial maps of prostate cancer transcriptomes reveal an unexplored landscape of heterogeneity publication-title: Nat. Commun. doi: 10.1038/s41467-018-04724-5 – volume: 29 start-page: 4320 year: 2011 end-page: 4326 ident: CR188 article-title: Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2011.35.5214 – volume: 18 start-page: 359 year: 2018 end-page: 376 ident: CR3 article-title: A history of exploring cancer in context publication-title: Nat. Rev. Cancer doi: 10.1038/s41568-018-0006-7 – volume: 196 start-page: 759 year: 2016 end-page: 766 ident: CR95 article-title: Coexpressed catalase protects chimeric antigen receptor-redirected T cells as well as bystander cells from oxidative stress-induced loss of antitumor activity publication-title: J. Immunol. doi: 10.4049/jimmunol.1401710 – volume: 18 start-page: 1332 year: 2017 end-page: 1341 ident: CR94 article-title: Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor publication-title: Nat. Immunol. doi: 10.1038/ni.3868 – volume: 33 start-page: 420 year: 2003 end-page: 425 ident: CR57 article-title: Tumor vascularity and tryptase-positive mast cells correlate with a poor prognosis in melanoma publication-title: Eur. J. Clin. Invest doi: 10.1046/j.1365-2362.2003.01152.x – volume: 16 start-page: 663 year: 2016 end-page: 673 ident: CR19 article-title: Oxygen availability and metabolic adaptations publication-title: Nat. Rev. Cancer doi: 10.1038/nrc.2016.84 – volume: 3 start-page: 721 year: 2003 end-page: 732 ident: CR153 article-title: Targeting HIF-1 for cancer therapy publication-title: Nat. Rev. Cancer doi: 10.1038/nrc1187 – volume: 125 start-page: 5591 year: 2012 end-page: 5596 ident: CR7 article-title: The tumor microenvironment at a glance publication-title: J. Cell Sci. doi: 10.1242/jcs.116392 – volume: 129 start-page: 1845 year: 2019 end-page: 1862 ident: CR171 article-title: Aspirin blocks formation of metastatic intravascular niches by inhibiting platelet-derived COX-1/thromboxane A(2) publication-title: J. Clin. Investig. doi: 10.1172/JCI121985 – volume: 6 year: 2020 ident: CR111 article-title: Sight and switch off: nerve density visualization for interventions targeting nerves in prostate cancer publication-title: Sci. Adv. doi: 10.1126/sciadv.aax6040 – volume: 20 year: 2019 ident: CR196 article-title: Landiolol, an ultra-short acting beta-1 blocker, for preventing postoperative lung cancer recurrence: study protocol for a phase III, multicenter randomized trial with two parallel groups of patients publication-title: Trials doi: 10.1186/s13063-019-3904-4 – volume: 10 start-page: 168 year: 2019 ident: CR53 article-title: Cold tumors: a therapeutic challenge for immunotherapy publication-title: Front Immunol. doi: 10.3389/fimmu.2019.00168 – volume: 3 start-page: 326 year: 2015 end-page: 332 ident: CR221 article-title: PD-L1 Expression correlates with tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy in breast cancer publication-title: Cancer Immunol. Res. doi: 10.1158/2326-6066.CIR-14-0133 – volume: 115 start-page: 3379 year: 2009 end-page: 3391 ident: CR110 article-title: Perineural invasion in cancer: a review of the literature publication-title: Cancer doi: 10.1002/cncr.24396 – volume: 17 start-page: 1291 year: 2018 end-page: 1302 ident: CR229 article-title: Metformin suppresses tumor progression by inactivating stromal fibroblasts in ovarian cancer publication-title: Mol. Cancer Ther. doi: 10.1158/1535-7163.MCT-17-0927 – volume: 16 start-page: 225 year: 2015 end-page: 238 ident: CR129 article-title: The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? publication-title: Cell Stem Cell doi: 10.1016/j.stem.2015.02.015 – volume: 24 start-page: 472 year: 2014 end-page: 478 ident: CR17 article-title: Hypoxia, lipids, and cancer: surviving the harsh tumor microenvironment publication-title: Trends Cell Biol. doi: 10.1016/j.tcb.2014.06.001 – volume: 145 start-page: 1387 year: 2019 end-page: 1403 ident: CR139 article-title: Beyond a chemopreventive reagent, aspirin is a master regulator of the hallmarks of cancer publication-title: J. Cancer Res. Clin. Oncol. doi: 10.1007/s00432-019-02902-6 – volume: 364 start-page: 485 year: 2019 end-page: 491 ident: CR185 article-title: Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response publication-title: Science doi: 10.1126/science.aau0447 – volume: 5 start-page: 18 year: 2019 ident: CR203 article-title: Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors publication-title: Cardiooncology – volume: 15 start-page: 563 year: 2015 end-page: 572 ident: CR29 article-title: Sympathetic nervous system regulation of the tumour microenvironment publication-title: Nat. Rev. Cancer doi: 10.1038/nrc3978 – volume: 122 start-page: 62 year: 2020 end-page: 71 ident: CR227 article-title: Hypoxia and hyperglycaemia determine why some endometrial tumours fail to respond to metformin publication-title: Brit. J. Cancer doi: 10.1038/s41416-019-0627-y – volume: 20 start-page: 143 year: 2020 end-page: 157 ident: CR28 article-title: Nerves in cancer publication-title: Nat. Rev. Cancer doi: 10.1038/s41568-019-0237-2 – volume: 4 start-page: 176 year: 2018 end-page: 196 ident: CR65 article-title: The evolving landscape of brain metastasis publication-title: Trends Cancer doi: 10.1016/j.trecan.2018.01.003 – volume: 1873 start-page: 188340 year: 2020 ident: CR248 article-title: Communication in tiny packages: exosomes as means of tumor-stroma communication publication-title: Biochim. Biophys. Acta Rev. Cancer doi: 10.1016/j.bbcan.2020.188340 – volume: 141 start-page: 2855 year: 2018 end-page: 2865 ident: CR211 article-title: Improved mobility with metformin in patients with myotonic dystrophy type 1: a randomized controlled trial publication-title: Brain doi: 10.1093/brain/awy231 – volume: 378 start-page: 2081 year: 2011 end-page: 2087 ident: CR180 article-title: Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(11)61049-0 – volume: 40 start-page: 122 year: 2019 end-page: 132 ident: CR176 article-title: Aspirin inhibits the proliferation of hepatoma cells through controlling GLUT1-mediated glucose metabolism publication-title: Acta Pharm. Sin. doi: 10.1038/s41401-018-0014-x – volume: 3 start-page: 328 year: 2007 end-page: 334 ident: CR177 article-title: Reduced risk of human lung cancer by selective cyclooxygenase 2 (COX-2) blockade: results of a case control study publication-title: Int. J. Biol. Sci. doi: 10.7150/ijbs.3.328 – volume: 169 start-page: 750 year: 2017 end-page: 765.e717 ident: CR69 article-title: Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses publication-title: Cell doi: 10.1016/j.cell.2017.04.014 – volume: 220 start-page: 88 year: 2020 end-page: 96 ident: CR150 article-title: Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance publication-title: Immunol. Lett. doi: 10.1016/j.imlet.2019.03.006 – volume: 4 start-page: 27066 year: 2015 ident: CR107 article-title: Biological properties of extracellular vesicles and their physiological functions publication-title: J. Extracell. Vesicles doi: 10.3402/jev.v4.27066 – volume: 78 start-page: 3926 year: 2018 end-page: 3937 ident: CR34 article-title: Fibrin stiffness mediates dormancy of tumor-repopulating Cells via a Cdc42-driven Tet2 epigenetic program publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-17-3719 – volume: 153 start-page: 104683 year: 2020 ident: CR141 article-title: Tumor microenvironment: Challenges and opportunities in targeting metastasis of triple negative breast cancer publication-title: Pharm. Res. doi: 10.1016/j.phrs.2020.104683 – volume: 5 start-page: 693 year: 2019 end-page: 703 ident: CR75 article-title: Lipid metabolism at the nexus of diet and tumor microenvironment publication-title: Trends Cancer doi: 10.1016/j.trecan.2019.09.007 – volume: 27 start-page: S247 year: 1996 end-page: 251 ident: CR241 article-title: Microvascular studies on the origins of perfusion-limited hypoxia publication-title: Br. J. Cancer Suppl. – volume: 284 start-page: 34211 year: 2009 end-page: 34222 ident: CR106 article-title: Microenvironmental pH is a key factor for exosome traffic in tumor cells publication-title: J. Biol. Chem. doi: 10.1074/jbc.M109.041152 – volume: 20 year: 2018 ident: CR234 article-title: Statin drugs to reduce breast cancer recurrence and mortality publication-title: Breast Cancer Res. doi: 10.1186/s13058-018-1066-z – volume: 343 start-page: 103729 year: 2019 ident: CR38 article-title: Cancer-associated fibroblasts in tumor microenvironment—accomplices in tumor malignancy publication-title: Cell Immunol. doi: 10.1016/j.cellimm.2017.12.003 – volume: 5 start-page: 9 year: 2017 end-page: 16 ident: CR226 article-title: Efficacy of PD-1 blockade is potentiated by metformin-induced reduction of tumor hypoxia publication-title: Cancer Immunol. Res. doi: 10.1158/2326-6066.CIR-16-0103 – volume: 578 start-page: 621 year: 2020 end-page: 626 ident: CR35 article-title: Mechanical regulation of glycolysis via cytoskeleton architecture publication-title: Nature doi: 10.1038/s41586-020-1998-1 – volume: 14 start-page: 3168 year: 2008 end-page: 3176 ident: CR167 article-title: Aspirin sensitizes cancer cells to TRAIL-Induced apoptosis by reducing survivin levels publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-07-4362 – volume: 78 start-page: 128 year: 2018 end-page: 139 ident: CR113 article-title: Influence of the neural microenvironment on prostate cancer publication-title: Prostate doi: 10.1002/pros.23454 – volume: 1871 start-page: 273 year: 2019 end-page: 280 ident: CR105 article-title: Targeting acidity in cancer and diabetes publication-title: Biochim. Biophys. Acta Rev. Cancer doi: 10.1016/j.bbcan.2019.01.003 – volume: 123 start-page: 2532 year: 2008 end-page: 2542 ident: CR108 article-title: Acidosis induces multi-drug resistance in rat prostate cancer cells (AT1) in vitro and in vivo by increasing the activity of the p-glycoprotein via activation of p38 publication-title: Int. J. Cancer doi: 10.1002/ijc.23818 – volume: 3 start-page: 198 year: 2019 end-page: 211 ident: CR170 article-title: Aspirin inhibits platelets from reprogramming breast tumor cells and promoting metastasis publication-title: Blood Adv. doi: 10.1182/bloodadvances.2018026161 – volume: 145 start-page: 2611 year: 2019 end-page: 2618 ident: CR5 article-title: Beyond the tumour microenvironment publication-title: Int. J. Cancer doi: 10.1002/ijc.32343 – volume: 97 start-page: 952 year: 2007 end-page: 956 ident: CR56 article-title: Decreased number of mast cells infiltrating into needle biopsy specimens leads to a better prognosis of prostate cancer publication-title: Br. J. Cancer doi: 10.1038/sj.bjc.6603962 – volume: 6 year: 2011 ident: CR146 article-title: Do stress responses promote leukemia progression? An animal study suggesting a role for epinephrine and prostaglandin-E-2 through reduced NK activity publication-title: PLos ONE doi: 10.1371/journal.pone.0019246 – volume: 75 start-page: 1777 year: 2015 end-page: 1781 ident: CR31 article-title: Nerve-cancer cell cross-talk: a novel promoter of tumor progression publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-14-3180 – volume: 35 start-page: 798 year: 2019 end-page: 815.e795 ident: CR230 article-title: Combination of Hypoglycemia and Metformin Impairs Tumor Metabolic Plasticity and Growth by Modulating the PP2A-GSK3beta-MCL-1 Axis publication-title: Cancer Cell. doi: 10.1016/j.ccell.2019.03.007 – volume: 1063 start-page: 13 year: 2018 end-page: 32 ident: CR83 article-title: Glutamine metabolism in cancer publication-title: Adv. Exp. Med. Biol. doi: 10.1007/978-3-319-77736-8_2 – volume: 1225 start-page: 137 year: 2020 end-page: 153 ident: CR243 article-title: The microbiome as a component of the tumor microenvironment publication-title: Adv. Exp. Med. Biol. doi: 10.1007/978-3-030-35727-6_10 – volume: 11 start-page: 4191 year: 2005 end-page: 4197 ident: CR189 article-title: Chemotherapy induces the expression of cyclooxygenase-2 in non-small cell lung cancer publication-title: Clin. Cancer Res doi: 10.1158/1078-0432.CCR-05-0108 – volume: 51 start-page: 27 year: 2019 end-page: 41 ident: CR40 article-title: Inflammation and cancer: triggers, mechanisms, and consequences publication-title: Immunity doi: 10.1016/j.immuni.2019.06.025 – volume: 19 start-page: 163 year: 2017 end-page: 194 ident: CR84 article-title: Glutaminolysis: a hallmark of cancer metabolism publication-title: Annu Rev. Biomed. Eng. doi: 10.1146/annurev-bioeng-071516-044546 – volume: 107 start-page: 5681 year: 2010 end-page: 5686 ident: CR149 article-title: Computational identification of gene-social environment interaction at the human IL6 locus publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.0911515107 – volume: 28 start-page: 864 year: 2018 end-page: 870 ident: CR215 article-title: Protective effect of metformin against thyroid cancer development: a population-based study in Korea publication-title: Thyroid doi: 10.1089/thy.2017.0550 – volume: 6 start-page: 236 year: 2020 end-page: 246 ident: CR66 article-title: Targeting the tumor microenvironment in colorectal peritoneal metastases publication-title: Trends Cancer doi: 10.1016/j.trecan.2019.12.008 – volume: 116 start-page: 6292 year: 2019 end-page: 6297 ident: CR173 article-title: Aspirin-triggered proresolving mediators stimulate resolution in cancer publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.1804000116 – volume: 98 start-page: 90 year: 2020 end-page: 97 ident: CR213 article-title: The multifaceted effects of metformin on tumor microenvironment publication-title: Semin Cell Dev. Biol. doi: 10.1016/j.semcdb.2019.05.010 – volume: 129 start-page: 5537 year: 2019 end-page: 5552 ident: CR143 article-title: beta2 adrenergic receptor-mediated signaling regulates the immunosuppressive potential of myeloid-derived suppressor cells publication-title: J. Clin. Invest. doi: 10.1172/JCI129502 – volume: 7 start-page: 65270 year: 2016 end-page: 65283 ident: CR232 article-title: Statins dose-dependently exert a significant chemopreventive effect on colon cancer in patients with chronic obstructive pulmonarydisease: A population-based cohort study publication-title: Oncotarget doi: 10.18632/oncotarget.11263 – volume: 111 start-page: 484 year: 2019 end-page: 489 ident: CR214 article-title: Metformin use and gastric cancer risk in diabetic patients after helicobacter pylori eradication publication-title: J. Natl Cancer Inst. doi: 10.1093/jnci/djy144 – volume: 4 start-page: 802 year: 2018 end-page: 809 ident: CR6 article-title: The multiple layers of the tumor environment publication-title: Trends Cancer doi: 10.1016/j.trecan.2018.10.002 – volume: 68 start-page: 11 year: 2019 end-page: 22 ident: CR200 article-title: beta-Adrenergic signaling blocks murine CD8(+) T-cell metabolic reprogramming during activation: a mechanism for immunosuppression by adrenergic stress publication-title: Cancer Immunol. Immunother. doi: 10.1007/s00262-018-2243-8 – ident: CR172 – volume: 48 start-page: 2258 year: 2006 end-page: 2262 ident: CR202 article-title: Protective effects of carvedilol against anthracycline-induced cardiomyopathy publication-title: J. Am. Coll. Cardiol. doi: 10.1016/j.jacc.2006.07.052 – volume: 121 start-page: 3444 year: 2015 end-page: 3451 ident: CR195 article-title: Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer publication-title: Cancer doi: 10.1002/cncr.29392 – volume: 343 start-page: 425 year: 1990 end-page: 430 ident: CR231 article-title: Regulation of the mevalonate pathway publication-title: Nature doi: 10.1038/343425a0 – volume: 32 start-page: 669 year: 2017 end-page: 683 e665 ident: CR45 article-title: An HIF-1alpha/VEGF-A axis in cytotoxic T cells regulates tumor progression publication-title: Cancer Cell. doi: 10.1016/j.ccell.2017.10.003 – volume: 17 start-page: 1498 year: 2011 end-page: U1207 ident: CR97 article-title: Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth publication-title: Nat. Med. doi: 10.1038/nm.2492 – volume: 95 start-page: 11715 year: 1998 end-page: 11720 ident: CR87 article-title: Mitochondrial reactive oxygen species trigger hypoxia-induced transcription publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.95.20.11715 – volume: 11 year: 2020 ident: CR49 article-title: Divergent mutational processes distinguish hypoxic and normoxic tumours publication-title: Nat. Commun. doi: 10.1038/s41467-019-14052-x – volume: 11 start-page: 2272 year: 2012 end-page: 2284 ident: CR89 article-title: CTGF drives autophagy, glycolysis and senescence in cancer-associated fibroblasts via HIF1 activation, metabolically promoting tumor growth publication-title: Cell Cycle doi: 10.4161/cc.20717 – volume: 312 start-page: 221 year: 2014 ident: CR239 article-title: Statin use may stop when illness is terminal, study says publication-title: JAMA doi: 10.1001/jama.2014.8845 – volume: 9 start-page: 628 year: 2019 end-page: 645 ident: CR70 article-title: Molecular profiling reveals unique immune and metabolic features of melanoma brain metastases publication-title: Cancer Disco. doi: 10.1158/2159-8290.CD-18-1489 – volume: 41 start-page: 562 year: 2012 end-page: 580 ident: CR91 article-title: Negative regulation of myeloid-derived suppressor cells in cancer publication-title: Immunol. Invest. doi: 10.3109/08820139.2012.685538 – volume: 26 start-page: 566 year: 2020 end-page: 576 ident: CR186 article-title: Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers publication-title: Nat. Med. doi: 10.1038/s41591-020-0805-8 – volume: 5 start-page: 4746 year: 2014 end-page: 4764 ident: CR224 article-title: Metformin limits the adipocyte tumor-promoting effect on ovarian cancer publication-title: Oncotarget doi: 10.18632/oncotarget.2012 – volume: 18 start-page: 41 year: 2019 end-page: 58 ident: CR159 article-title: Drug repurposing: progress, challenges and recommendations publication-title: Nat. Rev. Drug Disco. doi: 10.1038/nrd.2018.168 – volume: 79 start-page: 3155 year: 2019 end-page: 3162 ident: CR21 article-title: The tumor metabolic microenvironment: lessons from lactate publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-18-3726 – volume: 14 start-page: 771 year: 2010 end-page: 794 ident: CR100 article-title: Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer publication-title: J. Cell Mol. Med doi: 10.1111/j.1582-4934.2009.00994.x – volume: 17 start-page: 7015 year: 2011 end-page: 7023 ident: CR60 article-title: Mast cells in tumor microenvironment promotes the in vivo growth of pancreatic ductal adenocarcinoma publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-11-0607 – volume: 8 start-page: 519 year: 1927 end-page: 530 ident: CR77 article-title: The metabolism of tumors in the body publication-title: J. Gen. Physiol. doi: 10.1085/jgp.8.6.519 – volume: 183 start-page: 137 year: 2018 end-page: 151 ident: CR73 article-title: Live or let die: neuroprotective and anti-cancer effects of nutraceutical antioxidants publication-title: Pharm. Ther. doi: 10.1016/j.pharmthera.2017.10.012 – volume: 4 start-page: 335 year: 2018 end-page: 337 ident: CR14 article-title: Turning cold tumors hot by blocking TGF-beta publication-title: Trends Cancer doi: 10.1016/j.trecan.2018.03.005 – volume: 372 start-page: 2509 year: 2015 end-page: 2520 ident: CR184 article-title: PD-1 blockade in tumors with mismatch-repair deficiency publication-title: N. Engl. J. Med doi: 10.1056/NEJMoa1500596 – volume: 61 start-page: 6020 year: 2001 end-page: 6024 ident: CR47 article-title: Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo publication-title: Cancer Res. – volume: 18 start-page: 758 year: 2017 end-page: 770 ident: CR128 article-title: Mechanobiology of YAP and TAZ in physiology and disease publication-title: Nat. Rev. Mol. Cell Biol. doi: 10.1038/nrm.2017.87 – volume: 175 start-page: 691 year: 2015 end-page: 700 ident: CR238 article-title: Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial publication-title: JAMA Intern. Med doi: 10.1001/jamainternmed.2015.0289 – volume: 99 start-page: 608 year: 2007 end-page: 615 ident: CR179 article-title: A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence publication-title: J. Natl Cancer Inst. doi: 10.1093/jnci/djk132 – volume: 484 start-page: 50 year: 2020 end-page: 64 ident: CR240 article-title: Attenuation of the pro-inflammatory signature of lung cancer-derived mesenchymal stromal cells by statins publication-title: Cancer Lett. doi: 10.1016/j.canlet.2020.05.005 – volume: 358 start-page: 1443 year: 2017 end-page: 1448 ident: CR245 article-title: Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer publication-title: Science doi: 10.1126/science.aal5240 – volume: 29 start-page: 1949 year: 2011 end-page: 1955 ident: CR220 article-title: Tumor-infiltrating CD8(+) lymphocytes predict clinical outcome in breast cancer publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2010.30.5037 – volume: 64 start-page: 21 year: 2014 end-page: 27 ident: CR208 article-title: beta-Blockers promote angiogenesis in the mouse aortic ring assay publication-title: J. Cardiovasc Pharm. doi: 10.1097/FJC.0000000000000085 – volume: 122 start-page: 778 year: 2020 end-page: 788 ident: CR136 article-title: Anti-VEGF therapy resistance in ovarian cancer is caused by GM-CSF-induced myeloid-derived suppressor cell recruitment publication-title: Br. J. cancer doi: 10.1038/s41416-019-0725-x – volume: 132 start-page: 289 year: 2016 end-page: 307 ident: CR116 article-title: The importance of nerve microenvironment for schwannoma development publication-title: Acta Neuropathol. doi: 10.1007/s00401-016-1583-8 – volume: 533 start-page: 493 year: 2016 end-page: 498 ident: CR126 article-title: Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer publication-title: Nature doi: 10.1038/nature18268 – volume: 4 start-page: 371 year: 2020 end-page: 390 ident: CR117 article-title: The neural regulation of cancer publication-title: Annu. Rev. Cancer Biol. doi: 10.1146/annurev-cancerbio-030419-033349 – volume: 22 start-page: 1889 year: 2013 end-page: 1894 ident: CR197 article-title: Beta-blockers may reduce intrusive thoughts in newly diagnosed cancer patients publication-title: Psycho-Oncol. doi: 10.1002/pon.3233 – volume: 7 start-page: 264 year: 2018 ident: CR212 article-title: Metformin decreases risk of tuberculosis infection in Type 2 diabetes patients publication-title: J. Clin. Med. doi: 10.3390/jcm7090264 – volume: 162 start-page: 1257 year: 2015 end-page: 1270 ident: CR183 article-title: Cyclooxygenase-dependent tumor growth through evasion of immunity publication-title: Cell doi: 10.1016/j.cell.2015.08.015 – volume: 31 start-page: 2265 year: 2013 end-page: 2272 ident: CR209 article-title: Use of beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin ii receptor blockers, and risk of breast cancer recurrence: a Danish Nationwide Prospective Cohort Study publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2012.43.9190 – volume: 49 start-page: 6449 year: 1989 end-page: 6465 ident: CR76 article-title: Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review publication-title: Cancer Res. – volume: 8 start-page: 98 year: 1989 end-page: 101 ident: CR1 article-title: The distribution of secondary growths in cancer of the breast. 1889 publication-title: Cancer Metastasis Rev. – volume: 573 start-page: 532 year: 2019 end-page: 538 ident: CR121 article-title: Glutamatergic synaptic input to glioma cells drives brain tumour progression publication-title: Nature doi: 10.1038/s41586-019-1564-x – volume: 12 start-page: 298 year: 2012 end-page: 306 ident: CR55 article-title: The immune contexture in human tumours: impact on clinical outcome publication-title: Nat. Rev. Cancer doi: 10.1038/nrc3245 – volume: 35 start-page: 714 year: 2019 end-page: 720 ident: CR10 article-title: The fire within: cell-autonomous mechanisms in inflammation-driven cancer publication-title: Cancer Cell. doi: 10.1016/j.ccell.2019.04.001 – volume: 1 start-page: 313 year: 2017 end-page: 334 ident: CR33 article-title: Extracellular matrix remodeling and stiffening modulate tumor phenotype and treatment response publication-title: Annu. Rev. Cancer Biol. doi: 10.1146/annurev-cancerbio-050216-034431 – ident: CR72 – volume: 7 start-page: 77825 year: 2016 end-page: 77837 ident: CR199 article-title: Propranolol induces a favourable shift of anti-tumor immunity in a murine spontaneous model of melanoma publication-title: Oncotarget doi: 10.18632/oncotarget.12833 – volume: 196 start-page: 395 year: 2012 end-page: 406 ident: CR134 article-title: The extracellular matrix: a dynamic niche in cancer progression publication-title: J. Cell Biol. doi: 10.1083/jcb.201102147 – volume: 11 start-page: 6634 year: 2005 end-page: 6640 ident: CR190 article-title: Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-05-0436 – volume: 71 start-page: 2281 year: 2018 end-page: 2290 ident: CR201 article-title: Carvedilol for prevention of chemotherapy-related cardiotoxicity: The CECCY Trial publication-title: J. Am. Coll. Cardiol. doi: 10.1016/j.jacc.2018.02.049 – volume: 8 start-page: 73892 year: 2017 end-page: 73904 ident: CR205 article-title: Suppression of hypoxia-induced excessive angiogenesis by metformin via elevating tumor blood perfusion publication-title: Oncotarget doi: 10.18632/oncotarget.18029 – volume: 5 start-page: 411 year: 2019 end-page: 425 ident: CR249 article-title: The spatial and genomic hierarchy of tumor ecosystems revealed by single-cell technologies publication-title: Trends cancer doi: 10.1016/j.trecan.2019.05.009 – volume: 123 start-page: 3678 year: 2013 end-page: 3684 ident: CR81 article-title: Glutamine and cancer: cell biology, physiology, and clinical opportunities publication-title: J. Clin. Invest doi: 10.1172/JCI69600 – volume: 52 start-page: 613 year: 2018 end-page: 620 ident: CR192 article-title: Cyclooxygenase-2 expression is induced by celecoxib treatment in lung cancer cells and is transferred to neighbor cells via exosomes publication-title: Int. J. Oncol. – volume: 353 start-page: 78 year: 2016 end-page: 82 ident: CR252 article-title: Visualization and analysis of gene expression in tissue sections by spatial transcriptomics publication-title: Science doi: 10.1126/science.aaf2403 – volume: 38 start-page: 669 year: 2017 end-page: 686 ident: CR13 article-title: Reprogramming of the tumor in the hypoxic niche: the emerging concept and associated therapeutic strategies publication-title: Trends Pharm. Sci. doi: 10.1016/j.tips.2017.05.002 – volume: 25 start-page: 1282 year: 2017 end-page: 1293.e1287 ident: CR79 article-title: Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate Environments publication-title: Cell Metab. doi: 10.1016/j.cmet.2016.12.018 – volume: 141 start-page: 62 year: 2017 end-page: 71 ident: CR210 article-title: Pre- and post-diagnostic beta-blocker use and prognosis after colorectal cancer: results from a population-based study publication-title: Int. J. Cancer doi: 10.1002/ijc.30717 – volume: 8 start-page: 16804 year: 2018 ident: CR235 article-title: Statin-induced metabolic reprogramming in head and neck cancer: a biomarker for targeting monocarboxylate transporters publication-title: Sci. Rep. doi: 10.1038/s41598-018-35103-1 – volume: 21 start-page: 4652 year: 2015 end-page: 4662 ident: CR237 article-title: Mevalonate pathway antagonist suppresses formation of serous tubal intraepithelial carcinoma and ovarian carcinoma in mouse models publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-14-3368 – volume: 154 start-page: 318 year: 2018 end-page: 334 ident: CR187 article-title: Celecoxib inhibits mitochondrial O consumption, promoting ROS dependent death of murine and human metastatic cancer cells via the apoptotic signalling pathway publication-title: Biochem. Pharmacol. doi: 10.1016/j.bcp.2018.05.013 – volume: 24 start-page: 541 year: 2018 end-page: 550 ident: CR155 article-title: Understanding the tumor immune microenvironment (TIME) for effective therapy publication-title: Nat. Med. doi: 10.1038/s41591-018-0014-x – volume: 36 start-page: 418 year: 2019 end-page: 430.e6 ident: CR51 article-title: Tumor cell biodiversity drives microenvironmental reprogramming in liver cancer publication-title: Cancer Cell. doi: 10.1016/j.ccell.2019.08.007 – volume: 16 start-page: 619 year: 2016 end-page: 634 ident: CR82 article-title: From Krebs to clinic: glutamine metabolism to cancer therapy publication-title: Nat. Rev. Cancer doi: 10.1038/nrc.2016.71 – volume: 144 start-page: 646 year: 2011 end-page: 674 ident: CR4 article-title: Hallmarks of cancer: the next generation publication-title: Cell doi: 10.1016/j.cell.2011.02.013 – volume: 32 start-page: 195 year: 2003 end-page: 199 ident: CR58 article-title: Increase of mast cells and tumor angiogenesis in oral squamous cell carcinoma publication-title: J. Oral. Pathol. Med. doi: 10.1034/j.1600-0714.2003.00128.x – volume: 275 start-page: 89 year: 2009 end-page: 131 ident: CR59 article-title: The controversial role of mast cells in tumor growth publication-title: Int. Rev. Cell Mol. Biol. doi: 10.1016/S1937-6448(09)75004-X – volume: 31 start-page: 214 year: 2018 end-page: 234 ident: CR156 article-title: Implications of the tumor immune microenvironment for staging and therapeutics publication-title: Mod. Pathol. doi: 10.1038/modpathol.2017.156 – volume: 9 start-page: 164 year: 2018 ident: CR198 article-title: Adrenergic signaling: a targetable checkpoint limiting development of the antitumor immune response publication-title: Front. Immunol. doi: 10.3389/fimmu.2018.00164 – volume: 69 start-page: 88 year: 2019 end-page: 112 ident: CR162 article-title: Global patterns in excess body weight and the associated cancer burden publication-title: CA Cancer J. Clin. – volume: 4 start-page: 141 year: 2020 end-page: 158 ident: CR74 article-title: Lactate and acidity in the cancer microenvironment publication-title: Annu Rev. Canc Biol. doi: 10.1146/annurev-cancerbio-030419-033556 – volume: 3 start-page: 543 year: 2017 end-page: 546 ident: CR160 article-title: Repurposing drugs in oncology: next steps. trends publication-title: Trends Cancer doi: 10.1016/j.trecan.2017.06.007 – volume: 35 start-page: 3290 year: 2017 end-page: 3297 ident: CR233 article-title: Postdiagnosis statin use and mortality in danish patients with prostate cancer publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2016.71.8981 – volume: 27 start-page: 1395 year: 2016 end-page: 1402 ident: CR165 article-title: Aspirin use and the incidence of breast, colon, ovarian, and pancreatic cancers in elderly women in the Iowa Women’s Health Study publication-title: Cancer Causes Control doi: 10.1007/s10552-016-0804-8 – volume: 155 start-page: 479 year: 2018 end-page: 489.e7 ident: CR218 article-title: Metformin use is associated with longer progression-free survival of patients with diabetes and pancreatic neuroendocrine tumors receiving everolimus and/or somatostatin analogues publication-title: Gastroenterology doi: 10.1053/j.gastro.2018.04.010 – volume: 48 start-page: 812 year: 2018 end-page: 830.e814 ident: CR15 article-title: The Immune Landscape of Cancer publication-title: Immunity doi: 10.1016/j.immuni.2018.03.023 – volume: 35 start-page: 62 year: 2015 end-page: 70 ident: CR127 article-title: The mechanical microenvironment in cancer: How physics affects tumours publication-title: Semin. Cancer Biol. doi: 10.1016/j.semcancer.2015.09.001 – volume: 37 year: 2019 ident: CR137 article-title: The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications publication-title: Med. Oncol. doi: 10.1007/s12032-019-1329-2 – volume: 38 start-page: 225 year: 2013 end-page: 236 ident: CR92 article-title: Mitochondria are required for antigen-specific T cell activation through reactive oxygen species signaling publication-title: Immunity doi: 10.1016/j.immuni.2012.10.020 – volume: 71 start-page: 3505 year: 2011 end-page: 3515 ident: CR64 article-title: Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4(+) T cells to T-regulatory cells publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-10-4316 – volume: 501 start-page: 346 year: 2013 end-page: 354 ident: CR132 article-title: Influence of tumour micro-environment heterogeneity on therapeutic response publication-title: Nature doi: 10.1038/nature12626 – volume: 129 start-page: 5086 year: 2019 end-page: 5088 ident: CR144 article-title: Destress and do not suppress: targeting adrenergic signaling in tumor immunosuppression publication-title: J. Clin. Invest. doi: 10.1172/JCI133115 – volume: 7 start-page: 26 year: 2020 ident: CR204 article-title: Cardiotoxicity of anthracyclines publication-title: Front. Cardiovasc. Med. doi: 10.3389/fcvm.2020.00026 – volume: 9 start-page: 1556 year: 2019 ident: CR11 article-title: Understanding the complexity of the tumor microenvironment in K-ras mutant lung cancer: finding an alternative path to prevention and treatment publication-title: Front Oncol. doi: 10.3389/fonc.2019.01556 – volume: 118 start-page: 3835 year: 2008 end-page: 3837 ident: CR138 article-title: Tumor metabolism: cancer cells give and take lactate publication-title: J. Clin. Investig. – ident: CR12 – volume: 275 start-page: 25130 year: 2000 end-page: 25138 ident: CR88 article-title: Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1alpha during hypoxia: a mechanism of O2 sensing publication-title: J. Biol. Chem. doi: 10.1074/jbc.M001914200 – volume: 37 start-page: 624 year: 2019 end-page: 635 ident: CR191 article-title: Celecoxib with neoadjuvant chemotherapy for breast cancer might worsen outcomes differentially by COX-2 expression and ER status: exploratory analysis of the REMAGUS02 Trial publication-title: J. Clin. Oncol. doi: 10.1200/JCO.18.00636 – volume: 20 start-page: 174 year: 2020 end-page: 186 ident: CR61 article-title: A framework for advancing our understanding of cancer-associated fibroblasts publication-title: Nat. Rev. Cancer doi: 10.1038/s41568-019-0238-1 – volume: 341 start-page: 1236361 year: 2013 ident: CR25 article-title: Autonomic nerve development contributes to prostate cancer progression publication-title: Science doi: 10.1126/science.1236361 – volume: 513 start-page: 559 year: 2014 end-page: 563 ident: CR78 article-title: Functional polarization of tumour-associated macrophages by tumour-derived lactic acid publication-title: Nature doi: 10.1038/nature13490 – volume: 20 start-page: 85 year: 2020 end-page: 86 ident: CR140 article-title: The hypoxia-lactate axis tempers inflammation publication-title: Nature Rev. Immunol doi: 10.1038/s41577-019-0259-8 – volume: 200 start-page: 2479 year: 2018 end-page: 2488 ident: CR147 article-title: Blockade of host beta2-adrenergic receptor enhances graft-versus-tumor effect through modulating APCs publication-title: J. Immunol. doi: 10.4049/jimmunol.1701752 – volume: 568 start-page: 117 year: 2019 end-page: 121 ident: CR85 article-title: Breast cancer cells rely on environmental pyruvate to shape the metastatic niche publication-title: Nature doi: 10.1038/s41586-019-0977-x – volume: 95 start-page: 656 year: 2017 end-page: 661 ident: CR164 article-title: The anti-tumor effect of aspirin: what we know and what we expect publication-title: Biomed. Pharmacother. doi: 10.1016/j.biopha.2017.08.085 – volume: 203 start-page: 1105 year: 2019 end-page: 1110 ident: CR169 article-title: Cutting edge: targeting thrombocytes to rewire anticancer immunity in the tumor microenvironment and potentiate efficacy of PD-1 blockade publication-title: J. Immunol. doi: 10.4049/jimmunol.1900594 – volume: 352 start-page: 54 year: 2014 end-page: 58 ident: CR42 article-title: The role played by the microenvironment in site-specific metastasis publication-title: Cancer Lett. doi: 10.1016/j.canlet.2013.08.029 – volume: 129 start-page: 442 year: 2019 end-page: 451 ident: CR206 article-title: Hypoxia, angiogenesis, and metabolism in the hereditary kidney cancers publication-title: J. Clin. Invest. doi: 10.1172/JCI120855 – volume: 16 start-page: 399 year: 2016 end-page: 408 ident: CR115 article-title: Mechanisms of cancer dissemination along nerves publication-title: Nat. Rev. Cancer doi: 10.1038/nrc.2016.38 – volume: 117 start-page: 3748 year: 2020 end-page: 3758 ident: CR133 article-title: Hsp47 promotes cancer metastasis by enhancing collagen-dependent cancer cell-platelet interaction publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.1911951117 – volume: 107 start-page: 8788 year: 2010 end-page: 8793 ident: CR90 article-title: Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.1003428107 – volume: 6 start-page: 788 year: 2018 end-page: 797 ident: CR8 article-title: IL22 Promotes Kras-Mutant lung cancer by induction of a protumor immune response and protection of stemness properties publication-title: Cancer Immunol. Res. doi: 10.1158/2326-6066.CIR-17-0655 – volume: 180 start-page: 1098 year: 2020 end-page: 1114 e1016 ident: CR242 article-title: Tumor-derived retinoic acid regulates intratumoral monocyte differentiation to promote immune suppression publication-title: Cell doi: 10.1016/j.cell.2020.02.042 – volume: 103 start-page: 422 year: 2012 end-page: 432 ident: CR104 article-title: Pericellular pH homeostasis is a primary function of the Warburg effect: Inversion of metabolic systems to control lactate steady state in tumor cells publication-title: Cancer Sci. doi: 10.1111/j.1349-7006.2012.02206.x – volume: 2 start-page: 758 year: 2016 end-page: 770 ident: CR43 article-title: Hypoxia-inducible factors: master regulators of cancer progression publication-title: Trends Cancer doi: 10.1016/j.trecan.2016.10.016 – volume: 4 start-page: 431 year: 2003 end-page: 436 ident: CR182 article-title: Targeting cyclooxygenase-2 in human neoplasia: rationale and promise publication-title: Cancer Cell. doi: 10.1016/S1535-6108(03)00310-6 – volume: 9 year: 2018 ident: CR98 article-title: FABP4 as a key determinant of metastatic potential of ovarian cancer publication-title: Nat. Commun. doi: 10.1038/s41467-018-04987-y – volume: 1 start-page: 235 year: 2020 end-page: 248 ident: CR254 article-title: Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling publication-title: Nat. Cancer doi: 10.1038/s43018-019-0018-6 – volume: 578 start-page: 517 year: 2020 end-page: 518 ident: CR32 article-title: Tension in tumour cells keeps metabolism high publication-title: Nature doi: 10.1038/d41586-020-00314-y – volume: 73 start-page: 4429 year: 2013 end-page: 4438 ident: CR223 article-title: Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-13-0080 – volume: 20 start-page: 840 year: 2019 ident: CR152 article-title: Targeting tumor microenvironment for cancer therapy publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms20040840 – volume: 578 start-page: 449 year: 2020 end-page: 454 ident: CR114 article-title: Loss of p53 drives neuron reprogramming in head and neck cancer publication-title: Nature doi: 10.1038/s41586-020-1996-3 – volume: 5 start-page: 5 year: 2019 ident: CR124 article-title: Brain metastases publication-title: Nat. Rev. Dis. Prim. doi: 10.1038/s41572-018-0055-y – volume: 181 start-page: 1626 year: 2000 end-page: 1642.e20 ident: CR71 article-title: Single-cell mapping of human brain cancer reveals tumor-specific instruction of tissue-invading leukocytes publication-title: Cell doi: 10.1016/j.cell.2020.04.055 – volume: 124 start-page: 74 year: 2017 end-page: 91 ident: CR161 article-title: Drug repurposing in cancer publication-title: Pharmacol. Res. doi: 10.1016/j.phrs.2017.07.013 – volume: 11 start-page: 535 year: 2018 end-page: 541 ident: CR217 article-title: Dose-dependent relationship between metformin and colorectal cancer occurrence among patients with type 2 diabetes-A nationwide cohort study publication-title: Transl. Oncol. doi: 10.1016/j.tranon.2018.02.012 – volume: 15 start-page: 2042 year: 2008 end-page: 2052 ident: CR194 article-title: Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis publication-title: Ann. Surg. Oncol. doi: 10.1245/s10434-008-9890-5 – volume: 15 start-page: 1908 year: 2016 end-page: 1918 ident: CR102 article-title: Metformin is also effective on lactic acidosis-exposed melanoma cells switched to oxidative phosphorylation publication-title: Cell Cycle doi: 10.1080/15384101.2016.1191706 – volume: 367 year: 2020 ident: CR2 article-title: The biology, function, and biomedical applications of exosomes publication-title: Science doi: 10.1126/science.aau6977 – volume: 71 start-page: 606 year: 2018 end-page: 620.e607 ident: CR219 article-title: Metformin promotes antitumor immunity via endoplasmic-reticulum-associated degradation of PD-L1 publication-title: Mol. Cell. doi: 10.1016/j.molcel.2018.07.030 – volume: 82 start-page: 103 year: 2020 end-page: 126 ident: CR23 article-title: The acidic tumor microenvironment as a driver of cancer publication-title: Annu Rev. Physiol. doi: 10.1146/annurev-physiol-021119-034627 – volume: 9 start-page: 1115 year: 2007 end-page: 1124 ident: CR80 article-title: Aerobically derived lactate stimulates revascularization and tissue repair via redox mechanisms publication-title: Antioxid. Redox Signal doi: 10.1089/ars.2007.1674 – volume: 1 start-page: 23 year: 2013 ident: CR103 article-title: Acidosis induces reprogramming of cellular metabolism to mitigate oxidative stress publication-title: Cancer Metab. doi: 10.1186/2049-3002-1-23 – volume: 2 year: 2019 ident: CR50 article-title: Association of Long-term use of low-dose aspirin as chemoprevention with risk of lung cancer publication-title: JAMA Netw. Open doi: 10.1001/jamanetworkopen.2019.0185 – volume: 127 start-page: 679 year: 2006 end-page: 695 ident: CR62 article-title: Cancer metastasis: building a framework publication-title: Cell doi: 10.1016/j.cell.2006.11.001 – volume: 382 start-page: 2481 year: 2020 end-page: 2482 ident: CR181 article-title: Association between aspirin and hepatocellular carcinoma REPLY publication-title: N. Engl. J. Med – volume: 217 year: 2020 ident: CR246 article-title: Intratumoral accumulation of gut microbiota facilitates CD47-based immunotherapy via STING signaling publication-title: J. Exp. Med. doi: 10.1084/jem.20192282 – volume: 25 start-page: 23 year: 2014 end-page: 32 ident: CR93 article-title: The role of reactive oxygen species and metabolism on cancer cells and their microenvironment publication-title: Semin Cancer Biol. doi: 10.1016/j.semcancer.2013.12.007 – volume: 23 start-page: 533 year: 2013 end-page: 542 ident: CR193 article-title: β-Adrenergic system, a backstage manipulator regulating tumour progression and drug target in cancer therapy publication-title: Semin. Cancer Biol. doi: 10.1016/j.semcancer.2013.08.009 – volume: 6 year: 2016 ident: CR222 article-title: Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells publication-title: Sci. Rep. doi: 10.1038/srep18673 – volume: 4 start-page: 17 year: 2020 end-page: 40 ident: CR18 article-title: Metabolism in the tumor microenvironment publication-title: Annu. Rev. Cancer Biol. doi: 10.1146/annurev-cancerbio-030419-033333 – volume: 7 start-page: 52 year: 2016 ident: CR20 article-title: Lactate contribution to the tumor microenvironment: mechanisms, effects on immune cells and therapeutic relevance publication-title: Front Immunol. doi: 10.3389/fimmu.2016.00052 – volume: 38 start-page: 333 year: 2020 end-page: 342 ident: CR250 article-title: Integrating microarray-based spatial transcriptomics and single-cell RNA-seq reveals tissue architecture in pancreatic ductal adenocarcinomas publication-title: Nat. Biotechnol. doi: 10.1038/s41587-019-0392-8 – volume: 381 start-page: 133 year: 2016 end-page: 137 ident: CR125 article-title: Gap junction as an intercellular glue: Emerging roles in cancer EMT and metastasis publication-title: Cancer Lett. doi: 10.1016/j.canlet.2016.07.037 – volume: 6 start-page: 192 year: 2020 end-page: 204 ident: CR244 article-title: The cancer microbiome: distinguishing direct and indirect effects requires a systemic view publication-title: Trends Cancer doi: 10.1016/j.trecan.2020.01.004 – volume: 183 start-page: 137 year: 2018 ident: 280_CR73 publication-title: Pharm. Ther. doi: 10.1016/j.pharmthera.2017.10.012 – volume: 20 year: 2019 ident: 280_CR196 publication-title: Trials doi: 10.1186/s13063-019-3904-4 – volume: 12 start-page: 468 year: 2010 ident: 280_CR130 publication-title: Nat. Cell Biol. doi: 10.1038/ncb2048 – volume: 4 start-page: 802 year: 2018 ident: 280_CR6 publication-title: Trends Cancer doi: 10.1016/j.trecan.2018.10.002 – volume: 11 start-page: 6634 year: 2005 ident: 280_CR190 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-05-0436 – volume: 51 start-page: 27 year: 2019 ident: 280_CR40 publication-title: Immunity doi: 10.1016/j.immuni.2019.06.025 – volume: 179 start-page: 1661 year: 2019 ident: 280_CR63 publication-title: Cell doi: 10.1016/j.cell.2019.11.013 – volume: 533 start-page: 493 year: 2016 ident: 280_CR126 publication-title: Nature doi: 10.1038/nature18268 – ident: 280_CR12 doi: 10.1016/j.semcancer.2020.01.003 – volume: 16 start-page: 619 year: 2016 ident: 280_CR82 publication-title: Nat. Rev. Cancer doi: 10.1038/nrc.2016.71 – volume: 70 start-page: 7042 year: 2010 ident: 280_CR145 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-10-0522 – volume: 31 start-page: 2265 year: 2013 ident: 280_CR209 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2012.43.9190 – volume: 75 start-page: 1777 year: 2015 ident: 280_CR31 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-14-3180 – volume: 9 year: 2018 ident: 280_CR98 publication-title: Nat. Commun. doi: 10.1038/s41467-018-04987-y – volume: 368 start-page: 973 year: 2020 ident: 280_CR247 publication-title: Science doi: 10.1126/science.aay9189 – volume: 204 start-page: 280 year: 2020 ident: 280_CR27 publication-title: J. Immunol. doi: 10.4049/jimmunol.1900828 – volume: 573 start-page: 526 year: 2019 ident: 280_CR123 publication-title: Nature doi: 10.1038/s41586-019-1576-6 – volume: 7 start-page: 264 year: 2018 ident: 280_CR212 publication-title: J. Clin. Med. doi: 10.3390/jcm7090264 – volume: 4 start-page: 17 year: 2020 ident: 280_CR18 publication-title: Annu. Rev. Cancer Biol. doi: 10.1146/annurev-cancerbio-030419-033333 – volume: 27 start-page: 1395 year: 2016 ident: 280_CR165 publication-title: Cancer Causes Control doi: 10.1007/s10552-016-0804-8 – ident: 280_CR172 doi: 10.1155/2018/6380643 – volume: 118 start-page: 3930 year: 2008 ident: 280_CR101 publication-title: J. Clin. Investig. – volume: 102 start-page: 428 year: 2010 ident: 280_CR48 publication-title: Br. J. Cancer doi: 10.1038/sj.bjc.6605450 – volume: 15 start-page: 637 year: 2013 ident: 280_CR131 publication-title: Nat. Cell Biol. doi: 10.1038/ncb2756 – volume: 71 start-page: 606 year: 2018 ident: 280_CR219 publication-title: Mol. Cell. doi: 10.1016/j.molcel.2018.07.030 – volume: 382 start-page: 2481 year: 2020 ident: 280_CR181 publication-title: N. Engl. J. Med – volume: 124 start-page: 74 year: 2017 ident: 280_CR161 publication-title: Pharmacol. Res. doi: 10.1016/j.phrs.2017.07.013 – volume: 358 start-page: 1443 year: 2017 ident: 280_CR245 publication-title: Science doi: 10.1126/science.aal5240 – volume: 71 start-page: 3505 year: 2011 ident: 280_CR64 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-10-4316 – volume: 35 start-page: 798 year: 2019 ident: 280_CR230 publication-title: Cancer Cell. doi: 10.1016/j.ccell.2019.03.007 – volume: 6 start-page: 788 year: 2018 ident: 280_CR8 publication-title: Cancer Immunol. Res. doi: 10.1158/2326-6066.CIR-17-0655 – volume: 12 start-page: 5447 year: 1992 ident: 280_CR44 publication-title: Mol. Cell Biol. – volume: 501 start-page: 346 year: 2013 ident: 280_CR132 publication-title: Nature doi: 10.1038/nature12626 – volume: 68 start-page: 11 year: 2019 ident: 280_CR200 publication-title: Cancer Immunol. Immunother. doi: 10.1007/s00262-018-2243-8 – volume: 7 start-page: 65270 year: 2016 ident: 280_CR232 publication-title: Oncotarget doi: 10.18632/oncotarget.11263 – volume: 343 start-page: 103729 year: 2019 ident: 280_CR38 publication-title: Cell Immunol. doi: 10.1016/j.cellimm.2017.12.003 – volume: 95 start-page: 11715 year: 1998 ident: 280_CR87 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.95.20.11715 – volume: 24 start-page: 472 year: 2014 ident: 280_CR17 publication-title: Trends Cell Biol. doi: 10.1016/j.tcb.2014.06.001 – volume: 8 start-page: 519 year: 1927 ident: 280_CR77 publication-title: J. Gen. Physiol. doi: 10.1085/jgp.8.6.519 – volume: 115 start-page: 3379 year: 2009 ident: 280_CR110 publication-title: Cancer doi: 10.1002/cncr.24396 – volume: 203 start-page: 1105 year: 2019 ident: 280_CR169 publication-title: J. Immunol. doi: 10.4049/jimmunol.1900594 – volume: 7 start-page: 26 year: 2020 ident: 280_CR204 publication-title: Front. Cardiovasc. Med. doi: 10.3389/fcvm.2020.00026 – volume: 4 start-page: 335 year: 2018 ident: 280_CR14 publication-title: Trends Cancer doi: 10.1016/j.trecan.2018.03.005 – volume: 20 year: 2018 ident: 280_CR234 publication-title: Breast Cancer Res. doi: 10.1186/s13058-018-1066-z – volume: 64 start-page: 21 year: 2014 ident: 280_CR208 publication-title: J. Cardiovasc Pharm. doi: 10.1097/FJC.0000000000000085 – volume: 39 start-page: 880 year: 2016 ident: 280_CR26 publication-title: Trends Neurosci. doi: 10.1016/j.tins.2016.10.002 – volume: 18 start-page: 1332 year: 2017 ident: 280_CR94 publication-title: Nat. Immunol. doi: 10.1038/ni.3868 – volume: 35 start-page: 3290 year: 2017 ident: 280_CR233 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2016.71.8981 – volume: 19 start-page: 163 year: 2017 ident: 280_CR84 publication-title: Annu Rev. Biomed. Eng. doi: 10.1146/annurev-bioeng-071516-044546 – volume: 15 start-page: 264 year: 2010 ident: 280_CR151 publication-title: Alter. Med. Rev. – ident: 280_CR72 doi: 10.1101/2019.12.30.890517 – volume: 116 start-page: 6292 year: 2019 ident: 280_CR173 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.1804000116 – volume: 41 start-page: 562 year: 2012 ident: 280_CR91 publication-title: Immunol. Invest. doi: 10.3109/08820139.2012.685538 – volume: 6 year: 2016 ident: 280_CR222 publication-title: Sci. Rep. doi: 10.1038/srep18673 – volume: 124 start-page: 407 year: 2006 ident: 280_CR119 publication-title: Cell doi: 10.1016/j.cell.2005.10.041 – volume: 25 start-page: 23 year: 2014 ident: 280_CR93 publication-title: Semin Cancer Biol. doi: 10.1016/j.semcancer.2013.12.007 – volume: 573 start-page: 539 year: 2019 ident: 280_CR122 publication-title: Nature doi: 10.1038/s41586-019-1563-y – volume: 38 start-page: 333 year: 2020 ident: 280_CR250 publication-title: Nat. Biotechnol. doi: 10.1038/s41587-019-0392-8 – volume: 6 year: 2011 ident: 280_CR146 publication-title: PLos ONE doi: 10.1371/journal.pone.0019246 – volume: 528 start-page: 93 year: 2015 ident: 280_CR120 publication-title: Nature doi: 10.1038/nature16071 – volume: 5 start-page: 18 year: 2019 ident: 280_CR203 publication-title: Cardiooncology – volume: 41 start-page: 405 year: 2019 ident: 280_CR228 publication-title: Oncol. Rep. – volume: 5 start-page: 411 year: 2019 ident: 280_CR249 publication-title: Trends cancer doi: 10.1016/j.trecan.2019.05.009 – volume: 69 start-page: 4167 year: 2009 ident: 280_CR36 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-08-4859 – volume: 35 start-page: 62 year: 2015 ident: 280_CR127 publication-title: Semin. Cancer Biol. doi: 10.1016/j.semcancer.2015.09.001 – volume: 6 year: 2020 ident: 280_CR111 publication-title: Sci. Adv. doi: 10.1126/sciadv.aax6040 – volume: 367 year: 2020 ident: 280_CR2 publication-title: Science doi: 10.1126/science.aau6977 – volume: 145 start-page: 1387 year: 2019 ident: 280_CR139 publication-title: J. Cancer Res. Clin. Oncol. doi: 10.1007/s00432-019-02902-6 – volume: 343 start-page: 425 year: 1990 ident: 280_CR231 publication-title: Nature doi: 10.1038/343425a0 – volume: 9 year: 2018 ident: 280_CR251 publication-title: Nat. Commun. doi: 10.1038/s41467-018-04724-5 – volume: 48 start-page: 2258 year: 2006 ident: 280_CR202 publication-title: J. Am. Coll. Cardiol. doi: 10.1016/j.jacc.2006.07.052 – volume: 127 start-page: 679 year: 2006 ident: 280_CR62 publication-title: Cell doi: 10.1016/j.cell.2006.11.001 – volume: 353 start-page: 78 year: 2016 ident: 280_CR252 publication-title: Science doi: 10.1126/science.aaf2403 – volume: 107 start-page: 5681 year: 2010 ident: 280_CR149 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.0911515107 – volume: 78 start-page: 128 year: 2018 ident: 280_CR113 publication-title: Prostate doi: 10.1002/pros.23454 – volume: 51 start-page: 56 year: 2016 ident: 280_CR166 publication-title: Contemp. Clin. Trials doi: 10.1016/j.cct.2016.10.004 – volume: 378 start-page: 2081 year: 2011 ident: 280_CR180 publication-title: Lancet doi: 10.1016/S0140-6736(11)61049-0 – volume: 111 start-page: 484 year: 2019 ident: 280_CR214 publication-title: J. Natl Cancer Inst. doi: 10.1093/jnci/djy144 – volume: 99 start-page: 608 year: 2007 ident: 280_CR179 publication-title: J. Natl Cancer Inst. doi: 10.1093/jnci/djk132 – volume: 275 start-page: 89 year: 2009 ident: 280_CR59 publication-title: Int. Rev. Cell Mol. Biol. doi: 10.1016/S1937-6448(09)75004-X – volume: 15 start-page: 1908 year: 2016 ident: 280_CR102 publication-title: Cell Cycle doi: 10.1080/15384101.2016.1191706 – volume: 103 start-page: 422 year: 2012 ident: 280_CR104 publication-title: Cancer Sci. doi: 10.1111/j.1349-7006.2012.02206.x – volume: 129 start-page: 5086 year: 2019 ident: 280_CR144 publication-title: J. Clin. Invest. doi: 10.1172/JCI133115 – volume: 11 start-page: 4191 year: 2005 ident: 280_CR189 publication-title: Clin. Cancer Res doi: 10.1158/1078-0432.CCR-05-0108 – volume: 454 start-page: 436 year: 2008 ident: 280_CR9 publication-title: Nature doi: 10.1038/nature07205 – volume: 29 start-page: 4086 year: 2019 ident: 280_CR225 publication-title: Cell Rep. doi: 10.1016/j.celrep.2019.11.079 – volume: 309 start-page: 2563 year: 2013 ident: 280_CR163 publication-title: JAMA doi: 10.1001/jama.2013.6599 – volume: 120 start-page: 1565 year: 2007 ident: 280_CR178 publication-title: Int. J. Cancer doi: 10.1002/ijc.22514 – volume: 48 start-page: 812 year: 2018 ident: 280_CR15 publication-title: Immunity doi: 10.1016/j.immuni.2018.03.023 – volume: 122 start-page: 778 year: 2020 ident: 280_CR136 publication-title: Br. J. cancer doi: 10.1038/s41416-019-0725-x – volume: 3 start-page: 328 year: 2007 ident: 280_CR177 publication-title: Int. J. Biol. Sci. doi: 10.7150/ijbs.3.328 – volume: 129 start-page: 5537 year: 2019 ident: 280_CR143 publication-title: J. Clin. Invest. doi: 10.1172/JCI129502 – volume: 31 start-page: 214 year: 2018 ident: 280_CR156 publication-title: Mod. Pathol. doi: 10.1038/modpathol.2017.156 – volume: 364 start-page: 485 year: 2019 ident: 280_CR185 publication-title: Science doi: 10.1126/science.aau0447 – volume: 180 start-page: 1098 year: 2020 ident: 280_CR242 publication-title: Cell doi: 10.1016/j.cell.2020.02.042 – volume: 7 start-page: 52 year: 2016 ident: 280_CR20 publication-title: Front Immunol. doi: 10.3389/fimmu.2016.00052 – volume: 117 start-page: 3748 year: 2020 ident: 280_CR133 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.1911951117 – volume: 196 start-page: 759 year: 2016 ident: 280_CR95 publication-title: J. Immunol. doi: 10.4049/jimmunol.1401710 – volume: 118 start-page: 3835 year: 2008 ident: 280_CR138 publication-title: J. Clin. Investig. – volume: 123 start-page: 3678 year: 2013 ident: 280_CR81 publication-title: J. Clin. Invest doi: 10.1172/JCI69600 – volume: 71 start-page: 2281 year: 2018 ident: 280_CR201 publication-title: J. Am. Coll. Cardiol. doi: 10.1016/j.jacc.2018.02.049 – volume: 16 start-page: 399 year: 2016 ident: 280_CR115 publication-title: Nat. Rev. Cancer doi: 10.1038/nrc.2016.38 – volume: 122 start-page: 62 year: 2020 ident: 280_CR227 publication-title: Brit. J. Cancer doi: 10.1038/s41416-019-0627-y – volume: 97 start-page: 952 year: 2007 ident: 280_CR56 publication-title: Br. J. Cancer doi: 10.1038/sj.bjc.6603962 – volume: 1 start-page: 235 year: 2020 ident: 280_CR254 publication-title: Nat. Cancer doi: 10.1038/s43018-019-0018-6 – volume: 32 start-page: 669 year: 2017 ident: 280_CR45 publication-title: Cancer Cell. doi: 10.1016/j.ccell.2017.10.003 – volume: 95 start-page: 656 year: 2017 ident: 280_CR164 publication-title: Biomed. Pharmacother. doi: 10.1016/j.biopha.2017.08.085 – volume: 15 start-page: 563 year: 2015 ident: 280_CR29 publication-title: Nat. Rev. Cancer doi: 10.1038/nrc3978 – volume: 9 start-page: 1115 year: 2007 ident: 280_CR80 publication-title: Antioxid. Redox Signal doi: 10.1089/ars.2007.1674 – volume: 3 start-page: 721 year: 2003 ident: 280_CR153 publication-title: Nat. Rev. Cancer doi: 10.1038/nrc1187 – volume: 200 start-page: 2479 year: 2018 ident: 280_CR147 publication-title: J. Immunol. doi: 10.4049/jimmunol.1701752 – volume: 513 start-page: 559 year: 2014 ident: 280_CR78 publication-title: Nature doi: 10.1038/nature13490 – volume: 2 start-page: 758 year: 2016 ident: 280_CR43 publication-title: Trends Cancer doi: 10.1016/j.trecan.2016.10.016 – volume: 1871 start-page: 273 year: 2019 ident: 280_CR105 publication-title: Biochim. Biophys. Acta Rev. Cancer doi: 10.1016/j.bbcan.2019.01.003 – volume: 20 start-page: 85 year: 2020 ident: 280_CR140 publication-title: Nature Rev. Immunol doi: 10.1038/s41577-019-0259-8 – volume: 1 start-page: 313 year: 2017 ident: 280_CR33 publication-title: Annu. Rev. Cancer Biol. doi: 10.1146/annurev-cancerbio-050216-034431 – volume: 51 start-page: 308 year: 2019 ident: 280_CR52 publication-title: Nat. Genet. doi: 10.1038/s41588-018-0318-2 – volume: 568 start-page: 117 year: 2019 ident: 280_CR85 publication-title: Nature doi: 10.1038/s41586-019-0977-x – volume: 162 start-page: 1257 year: 2015 ident: 280_CR183 publication-title: Cell doi: 10.1016/j.cell.2015.08.015 – volume: 15 start-page: 2042 year: 2008 ident: 280_CR194 publication-title: Ann. Surg. Oncol. doi: 10.1245/s10434-008-9890-5 – volume: 18 start-page: 359 year: 2018 ident: 280_CR3 publication-title: Nat. Rev. Cancer doi: 10.1038/s41568-018-0006-7 – volume: 11 year: 2020 ident: 280_CR49 publication-title: Nat. Commun. doi: 10.1038/s41467-019-14052-x – volume: 4 start-page: 176 year: 2018 ident: 280_CR65 publication-title: Trends Cancer doi: 10.1016/j.trecan.2018.01.003 – volume: 1 start-page: 23 year: 2013 ident: 280_CR103 publication-title: Cancer Metab. doi: 10.1186/2049-3002-1-23 – volume: 348 start-page: 74 year: 2015 ident: 280_CR54 publication-title: Science doi: 10.1126/science.aaa6204 – volume: 129 start-page: 1845 year: 2019 ident: 280_CR171 publication-title: J. Clin. Investig. doi: 10.1172/JCI121985 – volume: 125 start-page: 5591 year: 2012 ident: 280_CR7 publication-title: J. Cell Sci. doi: 10.1242/jcs.116392 – ident: 280_CR16 doi: 10.1016/j.semcancer.2019.06.021 – volume: 368 start-page: 7 year: 2015 ident: 280_CR41 publication-title: Cancer Lett. doi: 10.1016/j.canlet.2015.07.039 – volume: 33 start-page: 420 year: 2003 ident: 280_CR57 publication-title: Eur. J. Clin. Invest doi: 10.1046/j.1365-2362.2003.01152.x – volume: 38 start-page: 669 year: 2017 ident: 280_CR13 publication-title: Trends Pharm. Sci. doi: 10.1016/j.tips.2017.05.002 – volume: 61 start-page: 6020 year: 2001 ident: 280_CR47 publication-title: Cancer Res. – volume: 1063 start-page: 13 year: 2018 ident: 280_CR83 publication-title: Adv. Exp. Med. Biol. doi: 10.1007/978-3-319-77736-8_2 – volume: 3 start-page: 198 year: 2019 ident: 280_CR170 publication-title: Blood Adv. doi: 10.1182/bloodadvances.2018026161 – volume: 121 start-page: 3444 year: 2015 ident: 280_CR195 publication-title: Cancer doi: 10.1002/cncr.29392 – volume: 217 year: 2020 ident: 280_CR246 publication-title: J. Exp. Med. doi: 10.1084/jem.20192282 – volume: 52 start-page: 613 year: 2018 ident: 280_CR192 publication-title: Int. J. Oncol. – volume: 115 start-page: 4787 year: 2010 ident: 280_CR236 publication-title: Blood doi: 10.1182/blood-2009-07-230508 – volume: 35 start-page: 714 year: 2019 ident: 280_CR10 publication-title: Cancer Cell. doi: 10.1016/j.ccell.2019.04.001 – volume: 17 start-page: 1291 year: 2018 ident: 280_CR229 publication-title: Mol. Cancer Ther. doi: 10.1158/1535-7163.MCT-17-0927 – volume: 30 start-page: 143 year: 2019 ident: 280_CR96 publication-title: Cell Metab. doi: 10.1016/j.cmet.2019.04.002 – volume: 21 start-page: 4652 year: 2015 ident: 280_CR237 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-14-3368 – volume: 284 start-page: 34211 year: 2009 ident: 280_CR106 publication-title: J. Biol. Chem. doi: 10.1074/jbc.M109.041152 – volume: 1873 start-page: 188340 year: 2020 ident: 280_CR248 publication-title: Biochim. Biophys. Acta Rev. Cancer doi: 10.1016/j.bbcan.2020.188340 – volume: 3 start-page: 326 year: 2015 ident: 280_CR221 publication-title: Cancer Immunol. Res. doi: 10.1158/2326-6066.CIR-14-0133 – volume: 372 start-page: 2509 year: 2015 ident: 280_CR184 publication-title: N. Engl. J. Med doi: 10.1056/NEJMoa1500596 – volume: 9 start-page: 1556 year: 2019 ident: 280_CR11 publication-title: Front Oncol. doi: 10.3389/fonc.2019.01556 – volume: 26 start-page: 566 year: 2020 ident: 280_CR186 publication-title: Nat. Med. doi: 10.1038/s41591-020-0805-8 – volume: 78 start-page: 5970 year: 2018 ident: 280_CR253 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-18-0747 – volume: 32 start-page: 135 year: 2017 ident: 280_CR67 publication-title: Cancer Cell. doi: 10.1016/j.ccell.2017.06.009 – volume: 78 start-page: 3926 year: 2018 ident: 280_CR34 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-17-3719 – volume: 24 start-page: 541 year: 2018 ident: 280_CR155 publication-title: Nat. Med. doi: 10.1038/s41591-018-0014-x – volume: 578 start-page: 449 year: 2020 ident: 280_CR114 publication-title: Nature doi: 10.1038/s41586-020-1996-3 – volume: 26 start-page: 259 year: 2020 ident: 280_CR68 publication-title: Nat. Med. doi: 10.1038/s41591-019-0750-6 – volume: 14 start-page: 771 year: 2010 ident: 280_CR100 publication-title: J. Cell Mol. Med doi: 10.1111/j.1582-4934.2009.00994.x – volume: 144 start-page: 646 year: 2011 ident: 280_CR4 publication-title: Cell doi: 10.1016/j.cell.2011.02.013 – volume: 18 start-page: 758 year: 2017 ident: 280_CR128 publication-title: Nat. Rev. Mol. Cell Biol. doi: 10.1038/nrm.2017.87 – volume: 293 start-page: 705 year: 2002 ident: 280_CR174 publication-title: Biochem. Biophys. Res. Commun. doi: 10.1016/S0006-291X(02)00271-1 – volume: 9 start-page: 164 year: 2018 ident: 280_CR198 publication-title: Front. Immunol. doi: 10.3389/fimmu.2018.00164 – volume: 39 start-page: 534 year: 2018 ident: 280_CR39 publication-title: Acta Pharm. Sin. doi: 10.1038/aps.2018.17 – volume: 4 start-page: 141 year: 2020 ident: 280_CR74 publication-title: Annu Rev. Canc Biol. doi: 10.1146/annurev-cancerbio-030419-033556 – volume: 169 start-page: 750 year: 2017 ident: 280_CR69 publication-title: Cell doi: 10.1016/j.cell.2017.04.014 – volume: 4 start-page: 371 year: 2020 ident: 280_CR117 publication-title: Annu. Rev. Cancer Biol. doi: 10.1146/annurev-cancerbio-030419-033349 – volume: 5 start-page: 4746 year: 2014 ident: 280_CR224 publication-title: Oncotarget doi: 10.18632/oncotarget.2012 – volume: 573 start-page: 532 year: 2019 ident: 280_CR121 publication-title: Nature doi: 10.1038/s41586-019-1564-x – volume: 154 start-page: 318 year: 2018 ident: 280_CR187 publication-title: Biochem. Pharmacol. doi: 10.1016/j.bcp.2018.05.013 – volume: 8 start-page: 73892 year: 2017 ident: 280_CR205 publication-title: Oncotarget doi: 10.18632/oncotarget.18029 – volume: 275 start-page: 25130 year: 2000 ident: 280_CR88 publication-title: J. Biol. Chem. doi: 10.1074/jbc.M001914200 – volume: 11 start-page: 2272 year: 2012 ident: 280_CR89 publication-title: Cell Cycle doi: 10.4161/cc.20717 – volume: 578 start-page: 517 year: 2020 ident: 280_CR32 publication-title: Nature doi: 10.1038/d41586-020-00314-y – volume: 175 start-page: 691 year: 2015 ident: 280_CR238 publication-title: JAMA Intern. Med doi: 10.1001/jamainternmed.2015.0289 – volume: 12 start-page: 409 year: 2018 ident: 280_CR207 publication-title: J. Am. Soc. Hypertens. doi: 10.1016/j.jash.2018.03.008 – volume: 5 start-page: 693 year: 2019 ident: 280_CR75 publication-title: Trends Cancer doi: 10.1016/j.trecan.2019.09.007 – volume: 4 start-page: 27066 year: 2015 ident: 280_CR107 publication-title: J. Extracell. Vesicles doi: 10.3402/jev.v4.27066 – volume: 153 start-page: 104683 year: 2020 ident: 280_CR141 publication-title: Pharm. Res. doi: 10.1016/j.phrs.2020.104683 – volume: 27 start-page: S247 year: 1996 ident: 280_CR241 publication-title: Br. J. Cancer Suppl. – volume: 69 start-page: 88 year: 2019 ident: 280_CR162 publication-title: CA Cancer J. Clin. doi: 10.3322/caac.21499 – volume: 79 start-page: 3155 year: 2019 ident: 280_CR21 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-18-3726 – volume: 578 start-page: 621 year: 2020 ident: 280_CR35 publication-title: Nature doi: 10.1038/s41586-020-1998-1 – volume: 2 year: 2019 ident: 280_CR50 publication-title: JAMA Netw. Open doi: 10.1001/jamanetworkopen.2019.0185 – volume: 5 start-page: 5 year: 2019 ident: 280_CR124 publication-title: Nat. Rev. Dis. Prim. doi: 10.1038/s41572-018-0055-y – volume: 49 start-page: 6449 year: 1989 ident: 280_CR76 publication-title: Cancer Res. – volume: 35 start-page: 347 year: 2019 ident: 280_CR135 publication-title: Cancer Cell. doi: 10.1016/j.ccell.2019.01.007 – volume: 77 start-page: 790 year: 2017 ident: 280_CR175 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-16-2400 – volume: 7 start-page: 46668 year: 2016 ident: 280_CR46 publication-title: Oncotarget doi: 10.18632/oncotarget.8694 – volume: 6 start-page: 236 year: 2020 ident: 280_CR66 publication-title: Trends Cancer doi: 10.1016/j.trecan.2019.12.008 – volume: 29 start-page: 1949 year: 2011 ident: 280_CR220 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2010.30.5037 – volume: 132 start-page: 289 year: 2016 ident: 280_CR116 publication-title: Acta Neuropathol. doi: 10.1007/s00401-016-1583-8 – volume: 20 start-page: 174 year: 2020 ident: 280_CR61 publication-title: Nat. Rev. Cancer doi: 10.1038/s41568-019-0238-1 – volume: 8 start-page: 98 year: 1989 ident: 280_CR1 publication-title: Cancer Metastasis Rev. – volume: 9 start-page: 628 year: 2019 ident: 280_CR70 publication-title: Cancer Disco. doi: 10.1158/2159-8290.CD-18-1489 – volume: 6 start-page: 192 year: 2020 ident: 280_CR244 publication-title: Trends Cancer doi: 10.1016/j.trecan.2020.01.004 – volume: 220 start-page: 88 year: 2020 ident: 280_CR150 publication-title: Immunol. Lett. doi: 10.1016/j.imlet.2019.03.006 – volume: 145 start-page: 2611 year: 2019 ident: 280_CR5 publication-title: Int. J. Cancer doi: 10.1002/ijc.32343 – volume: 16 start-page: 663 year: 2016 ident: 280_CR19 publication-title: Nat. Rev. Cancer doi: 10.1038/nrc.2016.84 – volume: 9 start-page: 702 year: 2019 ident: 280_CR30 publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-18-1398 – volume: 20 start-page: 840 year: 2019 ident: 280_CR152 publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms20040840 – volume: 29 start-page: 4320 year: 2011 ident: 280_CR188 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2011.35.5214 – volume: 37 start-page: 624 year: 2019 ident: 280_CR191 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.18.00636 – volume: 288 start-page: 10819 year: 2013 ident: 280_CR142 publication-title: J. Biol. Chem. doi: 10.1074/jbc.M112.442939 – volume: 98 start-page: 90 year: 2020 ident: 280_CR213 publication-title: Semin Cell Dev. Biol. doi: 10.1016/j.semcdb.2019.05.010 – volume: 155 start-page: 479 year: 2018 ident: 280_CR218 publication-title: Gastroenterology doi: 10.1053/j.gastro.2018.04.010 – volume: 10 start-page: 168 year: 2019 ident: 280_CR53 publication-title: Front Immunol. doi: 10.3389/fimmu.2019.00168 – volume: 18 start-page: 1201 year: 2012 ident: 280_CR148 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-11-0641 – volume: 196 start-page: 395 year: 2012 ident: 280_CR134 publication-title: J. Cell Biol. doi: 10.1083/jcb.201102147 – volume: 59 start-page: 379 year: 2019 ident: 280_CR154 publication-title: Annu. Rev. Pharm. doi: 10.1146/annurev-pharmtox-010818-021637 – volume: 4 start-page: 431 year: 2003 ident: 280_CR182 publication-title: Cancer Cell. doi: 10.1016/S1535-6108(03)00310-6 – volume: 144 start-page: 273 year: 2019 ident: 280_CR216 publication-title: Int. J. Cancer doi: 10.1002/ijc.31783 – volume: 36 start-page: 418 year: 2019 ident: 280_CR51 publication-title: Cancer Cell. doi: 10.1016/j.ccell.2019.08.007 – volume: 20 start-page: 143 year: 2020 ident: 280_CR28 publication-title: Nat. Rev. Cancer doi: 10.1038/s41568-019-0237-2 – volume: 3 start-page: 543 year: 2017 ident: 280_CR160 publication-title: Trends Cancer doi: 10.1016/j.trecan.2017.06.007 – volume: 28 start-page: 864 year: 2018 ident: 280_CR215 publication-title: Thyroid doi: 10.1089/thy.2017.0550 – volume: 341 start-page: 1236361 year: 2013 ident: 280_CR25 publication-title: Science doi: 10.1126/science.1236361 – volume: 11 start-page: 535 year: 2018 ident: 280_CR217 publication-title: Transl. Oncol. doi: 10.1016/j.tranon.2018.02.012 – volume: 141 start-page: 62 year: 2017 ident: 280_CR210 publication-title: Int. J. Cancer doi: 10.1002/ijc.30717 – volume: 22 start-page: 1889 year: 2013 ident: 280_CR197 publication-title: Psycho-Oncol. doi: 10.1002/pon.3233 – volume: 17 start-page: 1498 year: 2011 ident: 280_CR97 publication-title: Nat. Med. doi: 10.1038/nm.2492 – volume: 129 start-page: 442 year: 2019 ident: 280_CR206 publication-title: J. Clin. Invest. doi: 10.1172/JCI120855 – volume: 181 start-page: 1626 year: 2000 ident: 280_CR71 publication-title: Cell doi: 10.1016/j.cell.2020.04.055 – volume: 86 start-page: 360 year: 2015 ident: 280_CR112 publication-title: Neuron doi: 10.1016/j.neuron.2015.01.026 – volume: 141 start-page: 2855 year: 2018 ident: 280_CR211 publication-title: Brain doi: 10.1093/brain/awy231 – volume: 7 start-page: 388 year: 2014 ident: 280_CR168 publication-title: Cancer Prev. Res. (Philos.) doi: 10.1158/1940-6207.CAPR-13-0337 – volume: 7 start-page: 77825 year: 2016 ident: 280_CR199 publication-title: Oncotarget doi: 10.18632/oncotarget.12833 – volume: 38 start-page: 225 year: 2013 ident: 280_CR92 publication-title: Immunity doi: 10.1016/j.immuni.2012.10.020 – volume: 11 start-page: 671 year: 2011 ident: 280_CR99 publication-title: Nat. Rev. Cancer doi: 10.1038/nrc3110 – volume: 5 start-page: 9 year: 2017 ident: 280_CR226 publication-title: Cancer Immunol. Res. doi: 10.1158/2326-6066.CIR-16-0103 – volume: 8 start-page: 383 year: 2020 ident: 280_CR22 publication-title: Cancer Immunol. Res. doi: 10.1158/2326-6066.CIR-18-0749 – volume: 312 start-page: 221 year: 2014 ident: 280_CR239 publication-title: JAMA doi: 10.1001/jama.2014.8845 – volume: 25 start-page: 1282 year: 2017 ident: 280_CR79 publication-title: Cell Metab. doi: 10.1016/j.cmet.2016.12.018 – ident: 280_CR86 doi: 10.3390/cancers11081191 – volume: 161 start-page: 803 year: 2015 ident: 280_CR118 publication-title: Cell doi: 10.1016/j.cell.2015.04.012 – volume: 73 start-page: 4429 year: 2013 ident: 280_CR223 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-13-0080 – volume: 19 start-page: 1264 year: 2013 ident: 280_CR157 publication-title: Nat. Med. doi: 10.1038/nm.3337 – volume: 484 start-page: 50 year: 2020 ident: 280_CR240 publication-title: Cancer Lett. doi: 10.1016/j.canlet.2020.05.005 – volume: 14 start-page: 3168 year: 2008 ident: 280_CR167 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-07-4362 – volume: 17 start-page: 577 year: 2017 ident: 280_CR24 publication-title: Nat. Rev. Cancer doi: 10.1038/nrc.2017.77 – volume: 40 start-page: 122 year: 2019 ident: 280_CR176 publication-title: Acta Pharm. Sin. doi: 10.1038/s41401-018-0014-x – volume: 352 start-page: 54 year: 2014 ident: 280_CR42 publication-title: Cancer Lett. doi: 10.1016/j.canlet.2013.08.029 – volume: 8 start-page: 16804 year: 2018 ident: 280_CR235 publication-title: Sci. Rep. doi: 10.1038/s41598-018-35103-1 – volume: 381 start-page: 133 year: 2016 ident: 280_CR125 publication-title: Cancer Lett. doi: 10.1016/j.canlet.2016.07.037 – volume: 1225 start-page: 137 year: 2020 ident: 280_CR243 publication-title: Adv. Exp. Med. Biol. doi: 10.1007/978-3-030-35727-6_10 – volume: 107 start-page: 8788 year: 2010 ident: 280_CR90 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.1003428107 – volume: 181 start-page: 219 year: 2020 ident: 280_CR109 publication-title: Cell doi: 10.1016/j.cell.2020.03.034 – volume: 9 year: 2018 ident: 280_CR37 publication-title: Nat. Commun. doi: 10.1038/s41467-018-06641-z – volume: 82 start-page: 103 year: 2020 ident: 280_CR23 publication-title: Annu Rev. Physiol. doi: 10.1146/annurev-physiol-021119-034627 – volume: 18 start-page: 41 year: 2019 ident: 280_CR159 publication-title: Nat. Rev. Drug Disco. doi: 10.1038/nrd.2018.168 – volume: 23 start-page: 533 year: 2013 ident: 280_CR193 publication-title: Semin. Cancer Biol. doi: 10.1016/j.semcancer.2013.08.009 – volume: 37 year: 2019 ident: 280_CR137 publication-title: Med. Oncol. doi: 10.1007/s12032-019-1329-2 – volume: 32 start-page: 195 year: 2003 ident: 280_CR58 publication-title: J. Oral. Pathol. Med. doi: 10.1034/j.1600-0714.2003.00128.x – volume: 12 start-page: 298 year: 2012 ident: 280_CR55 publication-title: Nat. Rev. Cancer doi: 10.1038/nrc3245 – volume: 17 start-page: 7015 year: 2011 ident: 280_CR60 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-11-0607 – volume: 16 start-page: 225 year: 2015 ident: 280_CR129 publication-title: Cell Stem Cell doi: 10.1016/j.stem.2015.02.015 – volume: 352 start-page: aad3018 year: 2016 ident: 280_CR158 publication-title: Science doi: 10.1126/science.aad3018 – volume: 123 start-page: 2532 year: 2008 ident: 280_CR108 publication-title: Int. J. Cancer doi: 10.1002/ijc.23818 |
| SSID | ssj0001637754 ssib046561479 ssib044760960 ssib048695610 |
| Score | 2.6387837 |
| SecondaryResourceType | review_article |
| Snippet | Accumulating evidence shows that cellular and acellular components in tumor microenvironment (TME) can reprogram tumor initiation, growth, invasion,... |
| SourceID | pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 166 |
| SubjectTerms | 631/67/327 692/308/575 692/4028/67/327 Antidiabetics Cancer Research Cancer therapies Cell Biology Drug Repositioning Humans Internal Medicine Medicine Medicine & Public Health Metformin - therapeutic use Molecular Targeted Therapy Neoplasms - drug therapy Neoplasms - genetics Oncology Pathology Review Review Article Tumor Microenvironment - drug effects Tumor Microenvironment - genetics |
| SummonAdditionalLinks | – databaseName: Springer Nature HAS Fully OA dbid: AAJSJ link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3dS8MwED-GA_FF1PlRnRJBfNFim6RN9jj8YAzmiw58K_1IVXDt6FbQ_95L1m7OqeBzrjS5u9z9Lrm7AJwxEQqZRK7tdjxl88SndoRuz07RG0V-mFJBdTXy4N7vDXn_yXtqAK1rYUzSvmlpacx0nR12NUFjq_Mkqa6DptKxETc2dat21O1mt9t_6C9OVnym27pVFTIOkz98vOyFVqDlaobkt2tS433utmCzgo2kO5voNjRUtgOtLq4hH32Qc2ISOc0J-Q6sD6r78hbcoBaQcqyj-oSYql6d70TylEzLUV6QkU7H-1LrRpCEJEX5TAo1RhHk-iRhF4Z3t4_XPbt6N8GOEX9N7ciLvBRhWcgUTxCSuV6MjJdpJ3EV8ibEECVKHaYYxQg15rFMpFASIxk0wtLjIduDtSzP1AEQpWJfOjx1VIzYT8NxJToRTxC1xcJxlQVuzccgrpqK67ct3gJzuc1kMON9gLwPDO-Ddwsu5t-MZy01_qRu1-IJqu01CShnfkcwFL8Fp_Nh3Bj6tiPMVF4aGv3aoCeFBfszac5_x9ApM7Q8FoglOc8JdNPt5ZHs9cU03xacC4zZLLisNWIxrd9Xcfg_8iPYoEZb0Yp5bVibFqU6RvAzjU4qbf8ElIn_MQ priority: 102 providerName: Springer Nature |
| Title | The updated landscape of tumor microenvironment and drug repurposing |
| URI | https://link.springer.com/article/10.1038/s41392-020-00280-x https://www.ncbi.nlm.nih.gov/pubmed/32843638 https://www.proquest.com/docview/2436973745 https://www.proquest.com/docview/2437401587 https://pubmed.ncbi.nlm.nih.gov/PMC7447642 |
| Volume | 5 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9NAEB5Be-GCKOVhKNEiIS6wqu19-oRCSFVFaoWASrlZfqwLErFDEkvl0t_OzMZxSKv2kijxRo5nZ2e-eQO8EyYztswjHiXKcVnqmOeo9niF2ijXWRWbmKqRz8716YWcTNW0c7gtu7TKjUz0grpsCvKRH8dS6MQII9Wn-R9OU6MoutqN0HgI-9S6jLjaTHt1KqXRhND7z5raXm6jUtLqpIcP3iejBTWEo3l0IY0wRMOxq7MJhT1eorynVM2YSrFjG_KrXV12C6DezrO8EWz1OuzkCTzuwCcbrrnlAB64-ikcDms0vGd_2Xvm00G9n_0QviADsXZODoGS-YJgSpViTcVW7axZsBll8v1XJsdwCSsX7SVbuDnuXkNOiGdwcTL-MTrl3cgFXiB0W_Fc5apCRJcJJ0tEc5EqcM9slZSRQ-JkaN3kVSiciNG4LWRhS2ucRSMI5bdVMhPPYa9uavcSmHOFtqGsQlcgbCQk70ySyxIBX2HCyAUQbYiXFl0_chqL8Tv1cXFh0zXBUyR46gmeXgXwof_NfN2N497VR5s9SbuTuUy3fBTA2_4ynikKlGS1a1q_hgYVKmsCeLHewv52AvW5QKEVgNnZ3H4B9evevVL_-un7dhtiSBkH8HHDBtu_dfdTvLr_KV7Do9izJAo8dQR7q0Xr3iBOWuUDfxgGsD8cTr5P8P3z-PzrN_x2pEcD73vA17Pr8T9WNw9q |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VcoALopRHoAUjAReImthO7BwQqijVlj5OrbS3kMQOrcQmy-5GtH-K38iM81iWit56jOIkjmc8883LA_BGqExpk4d-mETWlybmfo5qzy9RG-VxVnLFqRr5-CQencmv42i8Br_7WhhKq-xlohPUpi7IR77DpYgTJZSMPk1_-tQ1iqKrfQuNli0O7dUvNNnmHw_2kL5vOd__cvp55HddBfwC0cnCz6M8KhG0ZMJKg4AljAqcli4TE9oYp44APi8DYQVH-62QhTZaWY04H0WUjmQm8L134C4q3oCMPTUe1LeUKiaLYLiO6ZjNZRRM6jgZ4IrzAeH3lGvUxgNqmYiGalfXEwi9M0f9QqmhnEq_uQ78y1XdeQ0QX8_r_Ce463Tm_kN40IFdttty5was2eoRbO5WaOhPrtg75tJPnV9_E_aQYVkzJQeEYa4AmVKzWF2yRTOpZ2xCmYN_leUxHMLMrPnOZnaK3FKT0-MxnN0KMZ7AelVX9hkwa4tYB7IMbIEwlSwHq5JcGgSYhQpC60HYL15adOefUxuOH6mLwwudtgue4oKnbsHTSw_eD89M29M_bhy91dMk7STBPF3yrQevh9u4hykwk1W2btwYaowYaeXB05aEw-cE4geBQtIDtULcYQCdD756p7o4d-eEK2JIyT340LPBclr__4vnN__FK7g3Oj0-So8OTg5fwH3u2BOFbbQF64tZY7cRoy3yl25jMPh22zvxDwXSRYo |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VrYS4IKA8AgWMBFwg2sR2YueAUGG7aimsKkSl3tI8HKjUTZbdjWj_Gr-OGeexLBW99RjFedgzHn_zBngpVKJ0nvquHwXGlXnI3RSPPbfA0ygNk4IrTtnIXybh3pH8dBwcb8DvLheGwio7mWgFdV5lZCMfcinCSAklg2HRhkUcjsbvZz9d6iBFntaunUbDIgfm4heqb4t3-yOk9SvOx7vfPu65bYcBN0OksnTTIA0KBDCJMDJH8OIHGf6iLqLcNyFOA8F8WnjCCI66XCYznWtlNGJ-FFc6kInA996ATUVa0QA2P-xODr923CylCkk_6K9DKrq58olJHUY9eLEWIfyism3buEcNFFFtbbN8PKGHCzxtKFCUUyI41557vn6SXoLHl6M8_3H12hN0fAdut9CX7TS8ehc2THkPtnZKVPunF-w1s8Go1sq_BSNkX1bPyByRM5uOTIFarCrYsp5WczalOMK_kvQYDmH5vP7O5maGvFORCeQ-HF0LOR7AoKxK8wiYMVmoPVl4JkPQSnqEUVEqc4SbmfJ844DfLV6ctdXQqSnHWWy98kLHzYLHuOCxXfD43IE3_TOzphbIlaO3O5rErVxYxCsuduBFfxt3NLlpktJUtR1DbRIDrRx42JCw_5xANCFQZDqg1ojbD6Bq4et3ytMftmq4IoaU3IG3HRusfuv_s3h89Syew03chfHn_cnBE7jFLXei5A22YbCc1-YpArZl-qzdGQxOrnsz_gFBsUsl |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+updated+landscape+of+tumor+microenvironment+and+drug+repurposing&rft.jtitle=Signal+transduction+and+targeted+therapy&rft.au=Jin%2C+Ming-Zhu&rft.au=Jin%2C+Wei-Lin&rft.date=2020-08-25&rft.eissn=2059-3635&rft.volume=5&rft.issue=1&rft.spage=166&rft_id=info:doi/10.1038%2Fs41392-020-00280-x&rft_id=info%3Apmid%2F32843638&rft.externalDocID=32843638 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2059-3635&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2059-3635&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2059-3635&client=summon |